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Xenobiotic	   Metabolizing	   Pathway	   works	   to	   detoxify	   the	   cell	   from	   numerous	  
carcinogenic,	  mutagenic,	  and	  toxic	  hydrophobic	  compounds.	  As	  a	  member	  of	  the	  phase	  
I	  enzymes	  (the	  first	  phase	   in	  the	  Xenobiotic	  Metabolizing	  Pathway)	  the	  Cytochrome	  P-­‐
450	  Family	  1	  Sub-­‐family	  B	  Protein	  1	  (Cyp1B1)	  works	  to	  attach	  an	  oxygen	  molecule	  to	  its	  
hydrophobic	   substrate.	   In	   performing	   this	   reaction,	   Cyp1B1	   often	   increases	   the	  
reactivity	  of	   the	  xenobiotic	  compound.	   If	   these	   reactive	  Cyp1B1	  products	  migrate	   into	  
the	   nucleus	   and	   they	   can	   cause	   damage	   by	   reacting	   with	   DNA.	   However,	   the	  
Glutathione	   S-­‐Transferase	   Theta	   1	   (GSTT1)	   and	   Glutathione	   S-­‐Transferase	   Mu	   1	  
(GSTM1),	  members	  of	  the	  phase	  II	  xenobiotic	  metabolizing	  pathway,	  are	  able	  to	  inactive	  
these	   reactive	   Cyp1B1	   products	   through	   the	   addition	   of	   a	   glutathione	   molecule.	  
Previous	  studies	  have	  shown	  that	  four	  single	  nucleotide	  polymorphisms,	  which	  lead	  to	  
amino	   acid	   substitutions,	   in	   the	   cyp1B1	   gene	   and	   gene	   deletions	   in	   gstt1	   and	   gstm1	  
genes	  lead	  to	  differences	  in	  cancer	  susceptibility.	  However,	  our	  analysis	  genotyped	  473	  
European	  Americans	  and	  177	  African	  Americans	  at	  each	  locus	  and	  found	  no	  correlation	  
between	   genotype	   and	   any	   of	   13	   tumor	   characteristics	   and	   breast	   cancer	   risk	   factors	  
that	   impact	  breast	   cancer	  progression	  or	  development.	  Due	   to	  high	   substrate	  overlap	  
between	  xenobiotic	  metabolizing	  enzymes,	  we	  hypothesize	  the	  cell	  can	  compensate	  for	  
differences	   in	  protein	   levels	  and	  enzymatic	  rates	  can	  by	   increased	  expression	  of	  highly	  
related	  enzymes.	  	  
	  iii	  
	  
We	   have	   also	   investigated	   the	   role	   of	   four	   cyp1B1	   polymorphisms	   on	   protein	  
stability	  using	  endogenous	  Cyp1B1	  variant	  proteins	  in	  human	  cell	  lines.	  We	  determined	  
that	   an	   Asparagine	   to	   Serine	   amino	   acid	   substitution	   at	   amino	   acid	   position	   453	  
decreases	   stability	  by	  20%	  compared	   to	  our	   ancestral	   control.	   This	   result	  was	  modest	  
when	  compared	   to	  previously	  published	  data,	  which	  used	  African	  Green	  Monkey	  cells	  
with	  overexpressed	  Cyp1B1	  proteins.	  Furthermore,	  we	  showed	  that	  Arginine	  to	  Glycine	  
substitutions	   at	   amino	   acid	   position	   48	   in	   conjunction	   with	   Alanine	   to	   Serine	  
substitution	  at	  amino	  acid	  position	  119	  increased	  stability	  by	  50%.	  We	  hypothesize	  that	  
these	  differences	  in	  protein	  stability	  have	  little	  effect	  on	  the	  production	  of	  carcinogenic	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1.1 Breast	  Cancer	  and	  the	  Knudson	  hypothesis:	  
Breast	   cancer	   is	   the	   most	   common	   form	   of	   cancer	   in	   women,	   and	   while	   less	  
common,	   it	   does	  occur	   in	  men.	   The	  National	  Cancer	   Institute	  estimates	   that	   almost	   a	  
quarter	  of	  a	  million	  people	  were	  diagnosed	  with	  breast	  cancer	   in	  2011	  and	  more	  than	  
40,000	  of	   those	  cases	  were	   fatal.	  The	  estimated	   lifetime	   risk	  of	  a	  woman	   living	   in	   the	  
United	  States	  being	  diagnosed	  with	  breast	  cancer	  is	  1	  in	  8	  (1).	  	  
While	  we	  are	  gaining	  new	   insight	   into	  breast	  cancer	   treatments	  every	  day,	   the	  
basic	  origins	  of	  cancer	  have	  been	  understood	   for	   sixty	  years.	   In	  1953,	  a	   statistician	  by	  
the	  name	  of	  Carl	  Nordling	  published	  a	  paper	  in	  the	  British	  Journal	  of	  Cancer	  describing	  
the	  multi-­‐mutational	  theory	  of	  cancer	  (50).	  His	  hypothesis	  stated	  that	  an	  accumulation	  
of	  mutations	  leading	  to	  an	  increase	  in	  the	  ratio	  between	  cell	  division	  and	  cell	  loss	  could	  
cause	  cancer.	  Nearly	   twenty	  years	   later,	  Dr.	  Alfred	  Knudson	  demonstrated	  statistically	  
that	  a	  specific	  set	  of	  mutations	  leads	  to	  the	  development	  of	  retinoblastoma	  (51).	  Over	  
the	   years,	   this	   theory	   of	   an	   accumulation	   of	   mutations	   has	   become	   known	   as	   the	  
Knudson	  Hypothesis.	  During	  the	  60	  years	  since	  it	  was	  first	  conceived,	  this	  hypothesis	  has	  
been	  well	  established.	   In	   fact,	   research	   into	   the	  development	  of	  colorectal	   cancer	  has	  
yielded	   a	   model	   demonstrating	   a	   series	   of	   mutations	   that	   lead	   to	   the	   formation	   of	  
malignant	   tumors	   (Figure	   1.1)	   (61).	   In	   early	   stages,	   loss	   of	   function	  mutations	   in	   the	  
adenomatous	   polyposis	   coli	   (APC)	   gene	   leads	   to	   an	   increase	   in	   β-­‐catenin,	   a	   protein	  
normally	   inhibited	   by	   the	   APC	   gene	   (62,	   63).	   Deregulation	   of	   β-­‐catenin	   leads	   to	   an	  











Figure	   1.1.	   	  Molecular	   Progression	   of	   Colorectal	   Cancer.	   Cells	   leave	   the	   crypt	   of	   the	  
intestines	   and	   differentiate	   to	   become	   normal	   epithelium.	   Through	   contact	   with	  
mutagenic	   compounds	   the	   normal	   epithelial	   cells	   undergo	   a	   series	   of	  mutations	   that	  
transform	  it	  to	  malignant	  metastatic	  tumor.	  
	  	  
(Source:	   Frank,	   Steven	   A.	  Dynamics	   of	   Cancer:	   Incidence,	   Inheritance,	   and	   Evolution.	  
Princeton,	  NJ:	  Princeton	  UP,	  2007.	  Print.)	  





an	  adenoma.	  To	  grow	  past	   this	  stage,	  a	  number	  of	  other	  mutations	  must	  occur	   in	   the	  
precancerous	   cells	   (61).	   Ras	   GTPase	   gain	   of	   function	  mutations,	  which	   are	   present	   in	  
50%	   of	   larger	   adenomas,	   allow	   for	   increased	   proliferation,	   increased	   invasion,	   and	  
eventually	  metastasis	  (64).	  As	  the	  adenomas	  grow	  and	  develop	  towards	  cancer,	  parts	  of	  
the	   long	   arm	   of	   chromosome	   18	   are	   lost	   (63,	   64).	   These	   deletion	   events	   occur	   in	  
approximately	  50%	  of	   large	  adenomas	  and	  75%	  of	  carcinomas	  (63).	  Loss	  of	  function	  in	  
the	   cell	   adhesion	   gene	   (Deleted	   in	   Colorectal	   Cancer;	  DCC)	   and	   cell	   cycle	   suppression	  
genes	   (SMAD2,	   SMAD4,	   and	   Transforming	   Growth	   Factor-­‐β)	   also	   allow	   for	   increased	  
growth	  of	  the	  adenoma	  (63,	  64).	  In	  the	  last	  step	  of	  colorectal	  cancer	  development,	  the	  
benign	  tumor	  must	  transform	  to	  a	  malignant	  tumor.	  The	  mutations	  needed	  to	  make	  this	  
switch	   usually	   involve	   rendering	   the	   tumor	   suppressor	   p53	   non-­‐functional.	   Either	  
through	  missense	  mutations,	   chromosomal	   breaks	   or	   gene	   deletions,	   loss	   of	   function	  
mutations	  in	  p53	  must	  occur	  in	  both	  copies	  to	  create	  a	  cancerous	  cell	  (64).	  Once	  p53	  is	  
inactivated,	  regulation	  of	  DNA	  repair,	  cell	  cycle,	  and	  apoptosis	  is	  lost,	  allowing	  the	  cells	  
to	  divide	  unconditionally	  (64).	  This	  in	  turn	  leads	  to	  decreased	  chromosomal	  stability	  and	  
the	  eventual	  formation	  of	  metastatic	  cancer	  (63,	  64,	  65).	  	  
	   Unlike	   colorectal	   cancer,	   mutations	   that	   lead	   to	   the	   development	   of	   breast	  
cancer	  are	  less	  understood,	  and	  it	  is	  clear	  that	  there	  are	  multiple	  pathways	  that	  lead	  to	  
the	   development	   of	   breast	   tumors.	   In	   2010,	   Schnitt	   describes	   the	   molecular	  
classification	   of	   breast	   cancer	   as	   four	   distinct	   subgroups	   based	   on	   hormone	   receptor	  
expression,	  histological	  grade,	  molecular	  markers	  and	   invasiveness	   (71).	  However,	   in	  a	  





mutation,	  germ	  line	  mutations,	  hormone	  receptor	  status,	  and	  other	  molecular	  markers,	  
was	   able	   to	   delineate	   ten	   breast	   cancer	   subgroups	   (72).	   Based	   on	   the	   high	  
heterogeneity	   of	   breast	   cancer,	   it	   is	   possible	   that	   as	   research	   increases,	   a	   more	  
informed	  study	  may	  find	  an	  even	  greater	  diversity	  of	  breast	  cancer	  subtypes.	  	  	  
Cancer	   causing	  mutations	   are	   created	   through	  multiple	   pathways.	   Some	   of	   these	  
mutations	  are	  caused	  by	  errors	  that	  occur	  during	  cellular	  activities	  (e.g.	  DNA	  synthesis	  
error	  during	  replication),	  while	  others	  may	  be	  due	  to	  external	  factors	  (e.g.	  Benzopyrene	  
entering	   the	   cell	   and	   intercalating	   into	   DNA,	   forming	   DNA	   adducts,	   and	   causing	  
mutations	  or	  alternatively	  an	  exposure	  to	  ultraviolet	  light	  that	  causes	  Thymine	  dimers).	  
Benzopyrene	   and	  many	   other	   environmental	  mutagenic	   compounds	   are	   hydrophobic,	  
which	  allows	  them	  to	  easily	  cross	  the	  hydrophobic	  cellular	  and	  nuclear	  membranes.	   In	  
order	   to	   reduce	   the	   effect	   of	   hydrophobic	   chemical	   mutagens	   and	   other	   potential	  
carcinogens,	  organisms	  use	  the	  xenobiotic	  metabolic	  pathway	  to	  modify	  and	  eliminate	  
these	  compounds.	  
1.2 The	  Xenobiotic	  Metabolic	  Pathway	  
As	   one	   of	   the	   main	   pathways	   of	   cellular	   detoxification,	   the	   xenobiotic	   metabolic	  
pathway	  consists	  of	  hundreds	  of	  different	  enzymes.	  These	  enzymes	  alter	   the	  chemical	  
structure	  and	  charge	  of	  many	  toxic	  hydrophobic	  compounds	  to	  facilitate	  their	  excretion	  
from	   the	   body.	   This	   pathway	   is	   also	   very	   active	   in	   the	   metabolism	   of	   many	  
pharmaceutical	   drugs	   and	   hormones.	   The	   xenobiotic	   metabolic	   pathway	   consists	   of	  
three	  phases	  designated	  phase	  1,	  2,	  and	  3	   (Figure	  1.2).	  Once	  a	  hydrophobic	   substrate	  






Figure	   1.2.	   Xenobiotic	   Metabolic	   Pathway:	   1)	   After	   a	   xenobiotic	  
compound	  (A)	  diffuses	  through	  the	  cell	  membrane,	  it	  is	  met	  by	  a	  phase	  I	  
metabolic	   pathway	   enzyme	   (B).	   2)	   In	   the	   modification	   step,	   a	   reactive	  
group	   is	   added	   by	   the	   phase	   I	   metabolic	   pathway	   enzyme	   to	   the	  
xenobiotic	  compound	  to	  produce	  a	  reactive	  xenobiotic	  compound	  (C).	  3)	  
The	  modified	   substrate	   (C)	  eventually	   is	  bound	  by	  a	  phase	   II	   xenobiotic	  
compound	   (D).	   4)	   The	   conjugation	   reaction	   of	   the	   phase	   II	   xenobiotic	  
compound	   attaches	   a	   large	   polar	   group	   to	   the	   modified	   xenobiotic	  
substrate	   to	   produce	   a	   hydrophilic	   molecule	   (E).	   5)	   The	   newly	   created	  
hydrophilic	  compound	  (E)	   is	  taken	  to	  the	  phase	  III	  protein	  known	  as	  the	  












phase	   1	   enzyme	   that	   adds	   reactive	   groups	   (e.g.	   a	   hydroxyl	   group	   added	   to	   Estradiol)	  
(Figure	   1.3	   and	   Figure	   1.4).	   After	   phase	   1	   modification,	   the	   substrate	   is	   ready	   for	   a	  
subsequent	  conjugation	  reaction	   in	  phase	  2,	   in	  which	  charged	  molecules	  are	  added	  to	  
the	   reactive	   phase	   1	   products.	   The	   addition	   of	   a	   charged	   moiety	   creates	   a	   polar	  
hydrophilic	   molecule.	   In	   phase	   3,	   a	  multidrug	   resistant	   protein	   channel	   spanning	   the	  
lipid	  bilayer	  can	  then	  export	  this	  hydrophilic	  molecule	  into	  the	  extracellular	  space	  where	  
its	   charged	   nature	   will	   allow	   it	   to	   enter	   the	   blood	   stream	   and	   be	   excreted	   from	   the	  
body.	  	  
The	   xenobiotic	   metabolic	   enzymes	   have	   a	   high	   amount	   of	   substrate	   overlap.	  
However,	   though	   the	   substrate	  may	   be	   the	   same,	   the	   reaction	   products	   often	   differ	  
from	  	  
enzyme	   to	   enzyme	   (Figure	   1.3).	   This	   difference	   in	   product	   can	   cause	   an	   issue.	   As	  
illustrated	  in	  Figure	  1.3,	  the	  hydroxylation	  of	  estradiol	  by	  Cyp1A1	  and	  Cyp1B1	  can	  lead	  
to	  2-­‐OHE2	  and	  4-­‐OHE2,	  respectively.	  While	  2-­‐OHE2	  can	  eventually	  undergo	  methylation	  
to	  become	  2-­‐MeOE2	   (a	  tumor	   inhibitor),	  4-­‐OHE2	  undergoes	  a	  conversion	   into	  a	  known	  
carcinogen	   (10,	  11).	  This	  phenomenon	  of	  mutagenic	  activation	   is	  not	  uncommon	  with	  
phase	  1	  enzymes,	  and	  the	  hydroxylation	  of	  xenobiotics	  can	  often	  create	  reactive	  oxygen	  
species,	  which	  lead	  to	  DNA	  adducts	  and	  genetic	  mutations	  (2).	  	  
1.3	  Polymorphic	  Variations	  and	  Cancer	  Risk	  
The	   Knudson	   Hypothesis	   not	   only	   describes	   the	   role	   of	   new	   mutations	   on	   cancer	  








Figure	   1.3	   The	   modification	   of	   Estradiol	   by	   Cyp1A1	   and	   Cyp1B1:	   Estradiol	   (E2),	   a	  
common	   estrogen	   derivative	   undergoes	   different	   modifications	   through	   different	  
reactions	  with	  Cyp1A1	  and	  Cyp1B1.	  In	  the	  Cyp1A1	  reaction	  E2	  is	  converted	  to	  2-­‐OHE2,	  
which	  can	  undergo	  further	  modifications	  to	  become	  a	  tumor	  inhibitor	  (2-­‐MeOE2).	  In	  
its	   reaction	   with	   Cyp1B1,	   E2	   is	   converted	   to	   4-­‐OHE2.	   After	   additional	   reactions,	   4-­‐
OHE2is	  transformed	  into	  E2-­‐3,4-­‐Q,	  a	  known	  carcinogen.	  	  
Source:	  Image	  was	  derived	  from:	  	  
Gregoraszczuk,	   Lucja.	   "Oestrogens,	   Xenoestrogens	   and	   Hormone-­‐Dependent	   Cancers.	  














Figure	  1.4	  Phase	  I	  and	  Phase	  II	  Xenobiotic	  Metabolic	  
Pathway	   Enzymes:	   Moving	   from	   left	   to	   right,	   the	  
molecule	   (X)	   is	   passing	   through	   the	   xenobiotic	  
metabolic	   pathway.	   First,	   it	   is	   modified	   by	   different	  
phase	  I	  enzymes,	  and	  then	  it	   is	  passed	  on	  to	  phase	  II	  
xenobiotic	  metabolic	  enzymes	  to	  undergo	  conjugation	  
reactions.	   Through	   this	   process,	   the	   hydrophobic	  










population	   there	   are	   a	   number	   of	   inherited	  mutations	   and	   polymorphisms	   that	   have	  
been	  shown	  to	   increase	  or	  decrease	   the	   risk	  of	   cancer	  development	   (4).	  For	  example,	  
inherited	   mutations	   in	   the	   DNA	   repair	   protein	   Breast	   Cancer	   1	   (BRCA1)	   and	   Breast	  
Cancer	  2	   (BRCA	  2)	  genes	  can	   lead	   to	  a	  significant	   increase	   in	  breast	  cancer	   risk	   (up	   to	  
80%)(5).	   Women	   who	   inherit	   these	   BRCA	   mutations	   also	   have	   a	   higher	   chance	   of	  
developing	  ovarian,	  colon,	  pancreatic,	  and	  thyroid	  cancers	  (5).	  In	  similar	  fashion,	  single	  
nucleotide	   polymorphisms	   and	   acquired	   missense	   mutations	   in	   the	   p53	   tumor	  
suppressor	   gene	   are	   found	   in	   20%	   to	  40%	  of	   breast	   cancers,	   and	  women	  who	   inherit	  
these	  defective	  p53	  genes	  more	  commonly	  develop	  breast	  cancer	  than	  any	  other	  cancer	  
(68).	   Other	   genes	   that	   play	   a	   fundamental	   role	   in	   genome	   integrity	   have	   also	   been	  
shown	   to	   have	   increased	   risk	   in	   breast	   cancer	   development.	   Chek2,	   a	   protein	   kinase	  
responsible	  for	  cell	  cycle	  arrest	  due	  to	  DNA	  damage,	  has	  been	  shown	  to	  contain	  deletion	  
mutations	  in	  some	  breast	  cancer	  patients.	  Studies	  have	  demonstrated	  that	  this	  deletion	  
is	   associated	   with	   a	   greater	   risk	   of	   breast	   cancer	   development,	   reoccurrence,	   and	  
mortality	   (73).	   Simillarly,	   mutations	   in	   the	   PI3K-­‐related	   protein	   kinase	   ATM	   that	  
decrease	   its	   ability	   to	   repair	   DNA	  double	   strand	   breaks	   have	   been	   shown	   to	   increase	  
breast	  cancer	  risk	  (74).	  A	  further	  example	  includes	  mutations	  and	  polymorphisms	  in	  the	  
tumor	  suppressor	  Her2	  tyrosine	  kinase,	  which	  promotes	  cell	  proliferation.	  These	  genetic	  
variations	   have	   been	   shown	   to	   only	   moderately	   increase	   the	   risk	   of	   breast	   cancer	  
development.	  However,	  these	  resulting	  changes	  in	  the	  Her2	  protein	  levels	  and	  function	  
are	   known	   to	   yield	   a	   poorer	   prognosis	   and	  higher	   risk	   of	   cancer	   recurrence	   (68).	   Like	  





is	  reasonable	  that	  multiple	  mutations	  that	  individually	  yield	  small	  increases	  in	  the	  risk	  of	  
cancer	  development	  can	  have	  significant	  effects	   in	  combination.	  Previous	  studies	  have	  
examined	   the	   effects	   of	   polymorphisms	   in	   the	   xenobiotic	   metabolism	   pathway	   on	  
cancer	   development	   in	   different	   populations	   throughout	   the	   world,	   yielding	   variable	  
results	   regarding	   the	   effects	   of	   each	   polymorphism	   (18-­‐20,	   23,	   27-­‐31,	   36-­‐43).	   By	  
measuring	   differences	   in	   catalytic	   activity	   and	   protein	   stability	   of	   the	   polymorphic	  
xenobiotic	   metabolizing	   pathway	   enzymes,	   several	   studies	   were	   able	   to	   provide	  
potential	   mechanisms	   for	   differences	   in	   associated	   risk	   (6,	   18-­‐26,	   32,	   40).	   We	  
hypothesized	   that	   by	   looking	   at	   single	   nucleotide	   polymorphisms	   (SNPs)	   and	   gene	  
deletions	  in	  the	  xenobiotic	  metabolic	  pathway	  genes	  in	  breast	  cancer	  patient	  DNA,	  we	  
would	  be	  able	   to	  determine	  which	  mutations	  contribute	   to	  an	   increased	  or	  decreased	  
likelihood	  of	  developing	  certain	  types	  of	  breast	  cancer.	  	  
1.4	  Polymorphisms	  in	  the	  Xenobiotic	  Metabolic	  Pathway	  and	  Their	  Enzymatic	  Effects	  
As	  indicated	  above,	  the	  xenobiotic	  metabolic	  pathway	  is	  composed	  of	  hundreds	  
of	   enzymes;	   however	   based	   on	   their	   expression	   patterns	   in	   breast	   tissue	   and	   breast	  
cancer	   cells	  and	  previously	  published	  data,	  3	  genes	   (cyp1B1,	   gstm1,	   and	   gstt1)	  with	  6	  
mutations	  in	  total	  were	  chosen	  for	  this	  study	  (18,	  19,	  20,	  27,	  36-­‐40).	  	  Cytochrome	  P450	  
family	   1	   subfamily	   B	   protein	   1	   (Cyp1B1)	   is	   considered	   a	   member	   of	   the	   phase	   I	  
xenobiotic	  metabolic	  enzyme	  superfamily	  Cytochrome	  P-­‐450,	  which	  includes	  18	  families	  
and	  43	  subfamilies	  and	  totals	  57	  genes	  and	  59	  pseudogenes	   (12).	  Studies	  have	  shown	  





development	  (60).	  By	  acting	  as	  a	  cellular	  detoxifier,	  Cyp	  enzymes	  have	  been	  shown	  to	  
deactivate	  and	  play	  a	  role	  in	  the	  expulsion	  of	  many	  cellular	  toxins.	  In	  addition,	  they	  also	  
activate	  many	   chemotherapeutic	   drugs	   (11,	   15-­‐17).	   However,	   Cyp	   enzymes	   also	   have	  
been	   shown	   to	   activate	   pro-­‐carcinogens,	   which	   can	   lead	   to	   the	   formation	   of	   DNA-­‐
Adducts	  and	  the	  development	  of	  genomic	  mutations	  (2,	  3,	  7,	  10,	  11,	  15-­‐17).	  	  
Cytochrome	  P-­‐450	  1B1	  Polymorphisms	  	  
While,	   less	   well	   known	   than	   the	   closely	   related	   Cytochrome	   P-­‐450	   family	   1	  
subfamily	  A	  protein	  1	  (Cyp1A1),	  Cyp1B1	  is	  produced	  at	  higher	  levels	  in	  breast	  tissue	  and	  
can	  yield	  quantitatively	  more	  reactive	  products	  (2,	  3,	  13,	  14)	  (Figure	  1.5)	  .	  In	  fact,	  cyp1B1	  
null	   mice	   have	   shown	   a	   significant	   reduction	   in	   the	   number	   of	   tumors	   caused	   by	  
Benzo[a]pyrene	  and	  DB[a,l]P,	  two	  common	  products	  of	  Cyp1A1	  and	  Cyp1B1	  (3).	  Also,	  as	  
described	  above,	  the	  conversion	  of	  Estradiol	  to	  the	  carcinogenic	  4-­‐OHE2	  is	  specific	  to	  the	  
Cyp1B1	  enzyme.	  Steady	  state	  levels	  of	  Cyp1B1	  are	  determined	  by	  the	  rate	  of	  synthesis	  
and	  the	  rate	  of	  degradation.	  Previous	  studies	  have	  found	  that	   the	  rate	  of	  degradation	  
for	  Cyp1B1	  is	  dependent	  upon	  movement	  through	  the	  proteasome,	  however	  the	  exact	  
mechanism	   in	  not	   fully	  understood	   (44).	   The	  cyp1B1	  gene	   is	   found	  on	  chromosome	  2	  
region	  22	  and	  contains	  3	  exons	  and	  2	  introns.	  As	  shown	  in	  figure	  1.6,	  translation	  begins	  
near	  the	  start	  of	  exon	  2	  and	  continues	  into	  exon	  3.	  Thus	  far,	  23	  variants	  of	  the	  cyp1B1	  
gene	   have	   been	   discovered,	   17	   of	  which	   lead	   to	   differences	   in	   amino	   acid	   sequence.	  
Several	  of	   these	  mutations	  have	  been	   thought	   to	   increase	   the	   risk	  of	   certain	   types	  of	  










Figure	  1.5	  Expression	  of	  Cyp1A1	  and	  Cyp1B1	  in	  normal	  and	  carcinogenic	  breast	  tissue:	  
Data	  was	  gathered	  using	  Genevestigator	  biomedical	  software.	  1)	  Cyp1B1	  expression	   in	  
normal	   breast	   tissue.	   2)	   Cyp1A1	   expression	   in	   normal	   breast	   tissue.	   3)	   Cyp1B1	  
expression	  in	  cancerous	  breast	  tissue.	  4)	  Cyp1A1	  expression	  in	  cancerous	  breast	  tissue.	  	  











Figure	   1.6	   Cyp1B1	   from	  Gene	   to	   Protein:	  
From	  top	   to	  bottom:	  Gene:	  a	  depiction	  of	  
the	   exons	   and	   introns	   within	   the	   cyp1b1	  
gene.	   mRNA:	   The	   Cyp1B1	   mRNA	  
transcribed	  from	  cyp1b1	  gene	  with	  introns	  
removed.	   Protein:	   A	   depiction	   of	   the	  
Cyp1B1	   coding	   sequence,	   which	   begins	   in	  
exon	  2,	   from	  mRNA	  that	   is	   translated	   into	  










with	  congenital	  glaucoma	  (6-­‐9).	  In	  particular,	  the	  four	  SNPs	  that	  have	  been	  examined	  in	  
this	  study,	  which	  each	  yield	  an	  amino	  acid	  change	  in	  the	  protein	  sequence,	  142	  C>G,	  355	  
G>T,	   4326	   C>G,	   and	   4390	   A>G	   (Figure	   1.7)	   all	   have	   been	   shown	   to	   alter	   enzymatic	  
efficiency	   or	   have	   been	   implicated	   in	   cancer	   development,	   either	   individually	   or	   in	  
combination	  (6,	  18-­‐26,	  32).	  For	  example,	  Shimada	  et	  al.	  reported	  an	  increase	  in	  the	  rate	  
of	   metabolism	   of	   a	   number	   of	   benzopyrene	   derivatives	   with	   the	   Cyp1B1	   355	   G>T	  
mutant	  enzyme	  (23).	  They	  also	  showed	  that	  the	  Cyp1B1	  4326	  C>G	  mutant	  enzyme	  and	  
the	   Cyp1B1	   355	   G>T	   and	   4326	   C>G	   double	   mutant	   enzyme	   produced	   4-­‐OHE2	   at	   an	  
increased	   rate.	   In	   a	   different	   study	   with	   different	   Cyp1B1	   haplotypes,	   Aklillu	   et	   al.	  
demonstrated	   that	   the	   4390	   A>G	   mutation	   could	   lead	   to	   a	   decrease	   in	   the	   rate	   of	  
production	  of	  benzopyrene	  derivatives,	  however	  they	  did	  not	  investigate	  the	  production	  
of	   4-­‐OHE2	   (22).	   These	   studies	   suggest	   that	   certain	   polymorphisms	   along	   the	   cyp1B1	  
gene	  could	  lead	  to	  a	  reduction	  in	  carcinogen	  production	  via	  the	  xenobiotic	  metabolizing	  
pathway	   yielding	   a	   reduction	   in	   the	   overall	   risk	   of	   tumor	   formation.	   However,	   other	  
polymorphisms	  may	  increase	  the	  rate	  of	  mutations	  and	  thus	  lead	  to	  an	  increase	  in	  risk	  
of	   tumor	   formation	   (23).	   Despite	   clear	   data	   about	   the	   production	   of	   mutagenic	  
compounds	   through	   Cyp1B1	   enzymatic	   activity,	   the	   determination	   of	   the	   role	   each	  
polymorphism	  plays	   in	  altering	  cancer	   risk	  has	  produced	  conflicting	  data.	   In	  2010,	   the	  
MARIE-­‐GENICA	  consortium	  showed	  an	  increase	  in	  breast	  cancer	  risk	  with	  mutations	  at	  
both	   142	   C>G	   and	   355	   G>T	   (20).	   Also,	  Miller	   et	   al.	   showed	   that	   in	   African	   American	  
women,	   but	   not	   in	   Caucasian	   women,	   mutations	   at	   site	   4326	   could	   increase	   breast	  











Figure	  1.7	  Polymorphisms	  in	  the	  Cyp1B1	  gene:	  Four	  
polymorphisms	   found	   in	   the	   Cyp1B1	   gene,	   which	  
yield	   amino	   acid	   substitutions	   and	   their	   relative	  
positions.	   142	   C>G	   causes	   a	   Arginine	   to	   Glycine	  
change	   at	   amino	   acid	   (AA)	   number	   48.	   355	   G>T	  
causes	  an	  Alanine	  to	  Serine	  change	  at	  AA	  119.	  4326	  
C>G	   yields	   a	   Leucine	   to	   Valine	   change	   at	   AA	   432.	  
4390	  A>G	  causes	  an	  Asparagine	  to	  Serine	  change	  at	  
AA	  453.	  	  





population	  a	  4326	  C>G	  mutation	  increased	  the	  risk	  of	  breast	  cancer	  (27).	  Other	  studies	  
have	  failed	  to	  show	  an	  association	  between	  cancer	  risk	  and	  Cyp1B1	  polymorphisms	  (28-­‐
31).	  However,	  many	  of	   these	  differing	  results	  could	  be	  due	  to	  race	  or	   lifestyle	   factors,	  
such	   as	   smoking,	   dietary	   habits,	   or	   local	   environmental	   conditions.	   Thus	   further	  
investigations	  into	  the	  role	  of	  cyp1B1	  polymorphisms	  in	  breast	  cancer	  development	  are	  
warranted.	  	  
Cytochrome	  P-­‐450	  1B1	  Polymorphisms	  and	  Protein	  Stability	  
Although	   the	   effects	   of	   the	   cyp1B1	   polymorphisms	   described	   above	   have	   been	  
characterized,	  the	  effects	  of	  these	  amino	  acid	  substitutions	  on	  Cyp1B1	  protein	  stability	  
need	   to	   be	   investigated.	   Consequently	  we	   used	  NetPhos	   2.0	   (49)	   to	   predict	   potential	  
protein	   phosphorylation	   sites	  which	  might	   impact	   protein	   stability	   (Figure	   1.8).	  When	  
the	  Cyp1B1	  enzyme	  had	  a	  serine	  substitution	  at	  position	  119	  or	  position	  453	  (the	  355	  
G>T	   and	   4390	   A>G	   polymorphisms,	   respectively)	   potential	   new	   phosphorylation	   sites	  
were	  formed.	  These	  newly	  created	  phosphorylation	  sites	  may	  cause	  the	  Cyp1B1	  enzyme	  
to	  be	  degraded	  more	  rapidly	  through	  the	  phosphodegron	  pathway	  of	  the	  proteasome.	  
In	   this	   pathway,	   two	   or	  more	   phosphorylated	   amino	   acids	   in	   close	   proximity	   to	   each	  
other	  on	  the	  protein	  of	  interest	  serve	  as	  recognition	  sites	  for	  the	  E3	  ubiquitin	  ligase.	  The	  
E3	  ubiquitin	  ligase	  is	  then	  able	  to	  tag	  the	  protein	  for	  degradation	  by	  the	  attachment	  of	  a	  
chain	  consisting	  of	  at	   least	  4	  ubiquitin	  molecules	  to	  a	  lysine	  on	  the	  protein	  of	   interest.	  
This	   tag	   directs	   the	   ubiquitinated	   protein	   of	   interest	   to	   the	   proteasome.	   The	  






Figure	   1.8	  Prediction	  of	   Potential	   Phosphorylation	  
Sites	   on	   Cyp1B1:	   From	   top	   to	   bottom:	   Frame	   1	  
depicts	   the	   ancestral	   Cyp1B1	   protein	   displaying	  
serine,	   threonine,	   and	   tyrosine	   phosphorylation	  
sites.	  The	  phosphorylation	   threshold	   is	  depicted	  by	  
a	   gray	   horizontal	   line.	   Frame	   2	   shows	   the	   Cyp1B1	  
enzyme	  with	  an	  alanine	  to	  serine	  substitution	  at	  site	  
119.	   As	   indicated	   by	   the	   black	   arrow,	   a	  
phosphorylation	  site	   is	  created	  by	  this	  substitution.	  
Frame	   3	   illustrates	   the	   potential	   phosphorylation	  
sequence	   of	   Cyp1B1	   with	   an	   asparagine	   to	   serine	  
amino	   acid	   substitution	   at	   site	   453.	   As	   marked	   by	  
the	   black	   arrow,	   the	   presence	   of	   the	   453	   serine	  
causes	   a	   neighboring	   serine	   at	   location	   458	   to	   be	  
phosphorylated.	  	  	  
Source:	   Netphos	   2.0:	   Sequence-­‐	   and	   structure-­‐
based	   prediction	   of	   eukaryotic	   protein	  
phosphorylation	  sites.	  Blom,	  N.,	  Gammeltoft,	  S.,	  and	  






a	   base.	  Once	   recognized	   by	   the	   proteasome,	   the	   ubiquitin	   tags	   are	   removed	   and	   the	  
protein	   of	   interest	   enters	   the	   proteasome	   to	   be	   degraded	   into	   amino	   acids.	   We	  
hypothesize	   that	   the	   variant	   Cyp1B1	   enzymes	   will	   be	   phosphorylated	   at	   the	   newly	  
created	   phosphorylation	   sites	   in	   addition	   to	   the	   normal	   phosphorylation	   sites.	   The	  
resulting	   increase	   in	   phosphorylation	   could	   cause	   the	   E3	   ubiquitin	   ligase	   to	   recognize	  
and	   bind	   Cyp1B1	   more	   efficiently	   as	   a	   substrate.	   Once	   bound,	   E3	   will	   transfer	   the	  
ubiquitin	  tag	  to	  the	  phosphorylated	  Cyp1B1.	  After	  a	  sufficient	  number	  of	  ubiquitin	  tags	  
have	   been	   transferred	   from	   E3	   molecules	   to	   the	   Cyp1B1	   protein,	   Cyp1B1	   will	   be	  
targeted	  by	  the	  proteasome	  for	  degradation	  (Figure	  1.9).	   	  Experimental	  data	  produced	  
by	  Bandiera	  et	  al.	  demonstrated	  that	  the	  asparagine	  to	  serine	  amino	  acid	  substitution	  at	  
site	  453	  caused	  a	  reduction	  in	  the	  stability	  of	  this	  Cyp1B1	  variant	  in	  monkey	  Cos-­‐1	  cells	  
(44).	  Therefore,	   it	   is	   likely	  that	  a	  Cyp1B1	  enzyme	  with	  an	  alanine	  to	  serine	  amino	  acid	  
substitution	  at	  position	  119	  would	  have	  decreased	  stability	  as	  well.	  Since	  these	  serine-­‐
encoding	  alleles	  are	  relatively	  common	  in	  human	  populations,	  the	  decreased	  stability	  of	  
the	   Cyp1B1	   variant	   enzymes	   could	   have	   a	   direct	   impact	   in	   steady	   state	   levels	   of	   the	  
protein.	   This	   reduction	   in	   Cyp1B1	   enzyme	   stability	   could	   decrease	   the	  metabolism	   of	  
hormones,	  pharmaceutical	  drugs	  and	  xenobiotic	  toxins	  and	  impact	  cancer	  development	  
and	   treatment.	   	   Therefore,	   it	   is	   important	   to	   determine	   the	   half-­‐life	   and	   steady	   state	  











Figure	   1.9	   Proteasome	   Degradation	  
Pathway:	  Ubiquitination	  and	  degradation	  of	  a	  
protein	   substrate	   by	   E1,	   E2	   and	   E3	   ubiquitin	  
ligases	  and	   the	  26S	  proteasome.	  Recognition	  
of	   certain	   amino	   acid	   or	   phosphorylation	  
sequences	   by	   the	   E3	   ubiquitin	   ligase	   causes	  
ubiquitin	   to	   be	   covalently	   attached	   to	   the	  
protein	  substrate.	  Once	  the	  protein	  substrate	  
has	   been	   tagged	   by	   a	   chain	   of	   4	   or	   more	  
ubiquitin	  molecules	   it	  will	  be	  targeted	  by	  the	  
proteasome	  for	  degradation.	  	  
Source:	   LeRoch,	   Karine.	   "Research	   Focus."	  Le	  
Roch	   Lab.	   UC	   Riverside,	   n.d.	   Web.	   10	   Dec.	  
2013.	  
	  






Like	  the	  phase	  I	  enzymes	  discussed	  above,	  phase	  2	  enzymes	  also	  play	  an	  important	  role	  
in	   cancer	   development	   and	   treatment.	   Composed	  mainly	   of	   transferases	   (an	   enzyme	  
that	   transfers	   a	   functional	   group	   from	   one	   molecule	   to	   another),	   phase	   2	   enzymes	  
detoxify	  many	  of	  the	  carcinogenic,	  mutagenic,	  and	  potentially	  toxic	  products	  of	  phase	  I	  
reactions.	   	  Glutathione	  S-­‐Transferases	   (GSTs),	  which	  make	  up	  approximately	  a	  sixth	  of	  
the	  phase	  2	  enzymes	  and	  are	  divided	  into	  five	  classes	  (Alpha,	  Mu,	  Pi,	  Kappa,	  and	  Theta),	  
form	   thioether	   conjugates	   between	   glutathione	   and	   the	   phase	   I	   xenobiotic	   product	  
(Figure	  1.10)	  (33).	  GSTs	  primarily	  metabolize	  reactive	  oxygen	  species	  and	  are	  often	  the	  
downstream	  detoxifier	  of	   the	  phase	   I	   Cytochrome	  P450	   reactions	   (34).	  Glutathione	  S-­‐
Transferase	   class	   Mu	   protein	   1	   (GSTM1)	   and	   Glutathione	   S-­‐Transferase	   class	   Theta	  
protein	   1	   (GSTT1)	   are	   two	   of	   the	   most	   studied	   GSTs	   in	   relation	   to	   cancer	   (35).	  
Independent	  deletions	  that	  remove	  either	  the	  gstm1	  or	  gstt1	  gene	  regions	  (Figure	  1.11)	  
are	  present	  at	  frequencies	  of	  62%	  (gstm1)	  and	  15%	  (gstt1)	  in	  European	  Americans	  and	  
26%	  (gstm1)	  and	  38%	  (gstt1)	   in	  African	  Americans	  and	  have	  been	  implicated	  in	  cancer	  
development	   (18,	   19,	   36-­‐40).	   For	   example,	  Miller	  et	   al.	   showed	   an	   increase	   in	   breast	  
cancer	   risk	   in	  women	  who	   lack	   the	  gstt1	   gene	   (19).	   	   Also,	   Helzlsouer	   et	   al.	   found	   an	  
increase	   in	   breast	   cancer	   risk	  with	   both	   the	  gstt1	  and	   the	  gstm1	   null	   genotypes	   (40).	  
However,	   other	   results	   have	   been	   contradictory	  with	   a	   number	   of	   reports	   finding	   no	  
association	  with	  gstt1	  or	  gstm1	  null	  genotypes	  and	  breast	  cancer	   risk	   (41-­‐43).	  As	  with	  
cyp1B1,	   these	   differences	   could	   be	   due	   to	   racial	   or	   lifestyle	   disparities	   and	   further	  










Figure	   1.10	   Conjugation	   of	   Glutathione	   by	   GST:	  	  
Glutathione	   is	   conjugated	   to	   the	   phase	   1	   xenobiotic	  
metabolic	  pathway	  product	  through	  a	  thioether	  bond.	  
This	   reaction	   is	   catalyzed	   by	   members	   of	   the	  
Glutathione	  S-­‐Transferase	  family.	  
Source:	  Townsend,	  Danyelle	  M.,	  and	  Kenneth	  D.	  Tew.	  
"The	  Role	  of	  Glutathione-­‐S-­‐transferase	   in	  Anti-­‐cancer	  
Drug	   Resistance."	  Oncogene	  22.47	   (2003):	   7369-­‐375.	  
Print.	  
	  












Figure	   1.11	   Homologous	   Recombination	   and	   the	   loss	   of	   GSTT1	   and	   GSTM1:	   High	  
homology	   sequences,	  which	   flank	   the	  gstt1	   and	  gstm1	   genes	  on	   chromosome	  22	  and	  
chromosome	   1,	   respectively,	   resulted	   in	   independent	   instances	   of	   homologous	  
recombination	  and	  the	  loss	  of	  the	  gstt1	  and	  gstm1	  genes.	  	  
Source:	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  Márcia	  Quinhones	  Pires	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   (2013).	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   Pharmacogenetics:	   State	  of	  
The	   Art,	   Tuberculosis	   -­‐	   Current	   Issues	   in	   Diagnosis	   and	   Management,	   Dr.	   Bassam	  
Mahboub	  (Ed.),	   ISBN:	  978-­‐953-­‐51-­‐1049-­‐1,	   InTech,	  DOI:	  10.5772/54984.	  Available	  from:	  
http://www.intechopen.com/books/tuberculosis-­‐current-­‐issues-­‐in-­‐diagnosis-­‐and-­‐
management/tuberculosis-­‐pharmacogenetics-­‐state-­‐of-­‐the-­‐art	  





1.5	  Research	  Goals	  
Chapter	  Two	  
Chapter	   two	  of	   this	  dissertation	   focuses	  on	  genotyping	  six	  SNPs	   in	   the	  phase	  1	  
and	   phase	   2	   xenobiotic	   metabolic	   enzymes	   described	   above	   and	   determining	   their	  
association	   with	   breast	   cancer	   risk	   factors	   and	   tumor	   characteristics.	   Since	  
polymorphisms	  in	  the	  xenobiotic	  metabolic	  pathway	  have	  been	  shown	  to	  yield	  changes	  
in	  mutagenic	  activity,	  these	  polymorphisms	  in	  phase	  1	  and	  phase	  2	  xenobiotic	  metabolic	  
enzyme	   genes	   could	   alter	   the	   risk	   of	   cancer	   development	   or	   tumor	   progression	   and	  
aggressiveness.	  	  	  
Cyp1b1	  Population	  Study	  
Studies	  have	   shown	   that	  Cyp1B1	  has	  an	   increased	   rate	  of	  mutagen	  production	  
compared	   to	   its	  most	   closely	   related	  enzyme,	  Cyp1A1	   (2).	   In	   addition,	   the	  amino	  acid	  
substitutions	   in	   Cyp1B1	   caused	  by	   the	   cyp1b1	   genetic	   polymorphisms	  have	   shown	   an	  
even	  higher	  rate	  of	  metabolism	  and	  mutagen	  production	  with	  certain	  substrates.	  Due	  to	  
the	   fact	   that	  polymorphisms	   in	   the	  cyp1b1	   gene	  yield	   an	   increased	   rate	  of	  mutagenic	  
compounds,	   and	   because	   it	   is	   the	   main	   phase	   1	   xenobiotic	   metabolic	   compound	   in	  
breast	  tissue,	  it	  is	  our	  hypothesis	  that	  the	  four	  SNPs	  in	  the	  cyp1b1	  gene	  will	  impact	  the	  







GSTT1	  and	  GSTM1	  Population	  Study	  
	   Phase	   2	   xenobiotic	  metabolic	   enzymes	   detoxify	   the	   cell	   from	   the	   reactive	   and	  
potentially	   mutagenic	   products	   produced	   from	   phase	   1	   reactions.	   Members	   of	   the	  
Glutathione	   S-­‐Transferase	   family	   neutralize	   these	   toxic	   substances	   by	   attaching	   a	  
glutathione	  molecule	   to	   the	   reactive	   site	   on	   the	  mutagenic	   compound.	  As	   two	  of	   the	  
most	  highly	  abundant	  phase	  2	  xenobiotic	  enzymes	   in	  breast	   tissue,	  GSTM1	  and	  GSTT1	  
play	   a	   pivotal	   role	   in	   detoxification	   of	   the	   cell	   (52).	   The	   absence	   of	   the	   GSTM1	   and	  
GSTT1	  enzymes	   caused	  by	   independent	  deletions	   in	   the	  gstm1	  and	  gstt1	   genes	   could	  
potentially	  yield	  a	  buildup	  of	  phase	  1	  mutagenic	  products.	  As	  stated	  above,	  a	  number	  of	  
these	   products	   have	   been	   shown	   to	   be	   carcinogenic	   (3,	   10,	   11).	   Because	  GSTM1	   and	  
GSTT1	  reduce	  the	   levels	  of	  mutagenic	  and	  carcinogenic	  compounds	   in	  breast	  tissue	  by	  
the	  addition	  of	  glutathione,	  we	  hypothesize	  that	  deletions	  in	  the	  gstm1	  and	  gstt1	  genes	  
speed	  the	  development	  of	  breast	  cancer.	  However,	  previous	  studies	  examining	  the	  role	  
of	   gstt1	   and	   gstm1	   gene	   deletion	   polymorphisms	   on	   breast	   cancer	   have	   found	  
inconsistent	  associations	  (19,	  40-­‐43).	  	  To	  test	  this	  hypothesis,	  we	  determined	  the	  gstt1	  
and	   gstm1	   genotypes	   in	   African	   American	   and	   European	   American	   breast	   cancer	  
patients.	  The	  resulting	  patient	  genotypes	  were	  then	  analyzed	  using	  logistic	  regression	  to	  
detect	  associations	  with	  breast	  cancer	  patient	  and	  tumor	  characteristics.	  	  
Chapter	  Three	  
	   Chapter	   three	   of	   this	   dissertation	   examines	   the	   effect	   of	   four	   amino	   acid	  





polymorphisms	  in	  the	  cyp1b1	  gene	  (142	  C>G,	  355	  G>T,	  4326	  C>G,	  and	  4390	  A>G)	  cause	  
amino	  acid	  substitutions	  (R48G,	  A119S,	  L432V,	  and	  N453S,	  respectively)	   in	  the	  Cyp1b1	  
enzyme.	   Numerous	   studies	   have	   been	   performed	   analyzing	   the	   role	   of	   these	  
substitutions	   on	   the	   enzymatic	   rate	   (6,	   18-­‐26,	   32).	   However,	   only	   two	   studies,	   which	  
assessed	   degradation	   through	   overexpression	   of	   Cyp1B1	   variants	   in	   African	   Green	  
Monkey	  cells,	  have	  examined	  how	  these	  substitutions	  affect	  protein	  stability	  and	  steady	  
state	  levels	  (21,	  44).	  Measuring	  the	  rate	  of	  endogenous	  Cyp1B1	  protein	  degradation	  in	  
human	   cells	   will	   allow	   us	   to	   more	   accurately	   assess	   the	   role	   that	   these	   amino	   acid	  
substitutions	  play	  on	  Cyp1B1	  stability.	  	  	  
Preliminary	   data	   gathered	   from	   NetPhos	   2.0	   predicted	   that	   amino	   acid	  
substitutions	   at	   119	   and	   453	   both	   yield	   changes	   in	   the	   phosphorylation	   status	   (49).	  
Therefore,	  we	  hypothesized	  that	  these	  substitutions	  at	  site	  119	  and	  453	  could	  cause	  a	  
decrease	  in	  Cyp1B1	  stability	  since	  the	  newly	  created	  phosphorylation	  sites	  could	  lead	  to	  
the	  formation	  of	  a	  phosphodegron.	  This	  phosphodegron	  would	  increase	  the	  recognition	  
and	   binding	   of	   E3	   ubiquitin	   ligase	   and	   thus	   would	   increase	   the	   rate	   of	   Cyp1B1	  
degradation	   through	   the	  proteasome	  pathway.	   Therefore,	  we	   determined	   the	   cyp1b1	  
genotype	  of	   three	  breast	   cancer	   cell	   lines	   (BT20,	  MCF7,	   and	  T47D)	  and	  measured	   the	  
steady	   state	   levels	   and	   stability	   of	   their	   Cyp1B1	   proteins.	   To	   verify	   the	   role	   of	   the	  
proteasome	   in	  Cyp1B1	  degradation,	  we	  used	   the	  proteasome	   inhibitor	  MG132	  with	   a	  
cycloheximide	  chase	  to	  measure	  differences	  in	  Cyp1B1	  degradation	  rates.	  	  






CHAPTER	  2:	  POLYMORPHISMS	  IN	  THE	  PHASE	  I	  AND	  PHASE	  II	  XENOBIOTIC	  METABOLIC	  PATHWAY	  
AND	  THEIR	  ASSOCIATION	  WITH	  PATIENT	  AND	  TUMOR	  CHARACTERISTICS	  






	   Xenobiotic	  metabolizing	  enzymes	  play	  an	   important	   role	   in	  detoxifying	   the	   cell	  
from	   toxic	   and	   often	   carcinogenic	   hydrophobic	   molecules.	   While	   enzymes	   such	   as	  
GSTM1	  and	  GSTT1	  work	  to	  create	  non-­‐reactive	  polar	  molecules	  from	  these	  hydrophobic	  
compounds,	   in	   the	   process	   of	   detoxification,	   the	   enzyme	   Cyp1B1	   often	   produces	  
mutagens.	  Four	  single	  nucleotide	  polymorphisms	  found	   in	  the	  cyp1b1	  gene	  have	  been	  
experimentally	   shown	   to	   increase	   this	  mutagen	  production.	   Furthermore,	  deletions	  of	  
the	   gstm1	   and	   gstt1	   genes	   reduce	   the	   cells	   ability	   to	   safely	   remove	   these	   toxic	  
compounds.	  As	   such,	  we	  hypothesized	   that	  polymorphisms	   in	   the	  cyp1b1¸	  gstm1,	   and	  
gstt1	   genes	   would	   increase	   the	   mutagenic	   rate,	   and	   thus	   could	   be	   associated	   with	  
breast	  cancer	  risk	  factors	  and	  tumor	  characteristics.	  To	  test	  this	  hypothesis,	  genotypes	  
were	  determined	  at	  each	  locus	  for	  601	  European	  American	  and	  African	  American	  breast	  
cancer	  patients.	  Logistic	  regression	  was	  used	  to	  compare	  patient	  genotypes	  with	  breast	  
cancer	   tumor	  and	  patient	  characteristics.	  Our	  analysis	   found	  no	  significant	  association	  
between	  any	  of	  the	  tested	  polymorphisms	  of	  the	  xenobiotic	  metabolic	  pathway	  and	  any	  
of	  the	  breast	  cancer	  tumor	  and	  patient	  characteristics	  analyzed	  in	  this	  study.	  	  
2.1	  Introduction	  
Breast	  cancer	  is	  known	  to	  be	  one	  of	  the	  most	  commonly	  occurring	  and	  deadliest	  
cancers	  in	  the	  world.	  For	  women	  in	  the	  United	  States,	  breast	  cancer	  ranks	  as	  the	  second	  
highest	  diagnosed	  cancer	  and	  the	  number	  two	  cause	  of	  cancer	  related	  death.	  However,	  
disparities	   in	   breast	   cancer	   type,	   aggressiveness,	   and	   age	   at	   diagnosis	   exist	   between	  





with	  our	  laboratory,	  it	  was	  shown	  that	  African	  American	  women	  in	  South	  Carolina	  have	  
a	  younger	  age	  of	  diagnosis	  than	  that	  of	  their	  European	  American	  peers	  (AA:	  58.1	  +	  14.8,	  
EA:	  62.5	  +	  13.9)(66).	  In	  addition,	  Bauer	  et	  al.	  showed	  that	  African	  American	  women	  are	  
also	  at	  higher	  risk	  to	  develop	  triple	  negative	  (Estrogen	  receptor	  negative,	  Progesterone	  
receptor	  negative,	  Her2	  negative)	  breast	  cancer,	  a	  prognosis	  associated	  with	  increased	  
aggressiveness	   and	   poorer	   survival	   rates	   (67).	   Furthermore,	   it	   has	   been	   shown	   that	  
African	  American	  breast	  cancer	  patients	  also	  have	  a	  higher	  incidence	  of	  developing	  the	  
most	  aggressive	  subtype	  of	  breast	  cancer	  (Estrogen	  Receptor	  negative	  /	  Grade	  3	  tumor)	  
compared	  to	   that	  of	   the	  European	  American	  breast	  cancer	  patients	   (AA:	  33%	  of	  study	  
population,	   EA:	   16%	   of	   study	   population)	   (66).	   To	   understand	   the	   differences	   in	  
aggressiveness,	  breast	  cancer	  type,	  and	  age	  at	  diagnosis	  between	  African	  American	  and	  
European	   American	   women	   it	   is	   essential	   to	   examine	   genomic	   polymorphisms	   that	  
could	  alter	  mutational	  rate.	  
In	  an	  effort	   to	  examine	  the	   impact	  of	  polymorphisms	  on	  the	  risk	  of	  developing	  
aggressive	   forms	   of	   breast	   cancer,	   we	   began	   studying	   xenobiotic	   metabolic	   pathway	  
genes.	   The	   xenobiotic	   metabolic	   pathway	   has	   been	   shown	   to	   participate	   in	   the	  
metabolism	  of	  numerous	  hydrophobic	  toxins,	  drugs,	  and	  hormones.	  Studies	  have	  shown	  
that	  enzymes	  in	  phase	  1	  of	  this	  pathway	  often	  increase	  the	  reactivity	  of	  many	  of	  these	  
compounds	   which	   can	   lead	   to	   the	   formation	   of	   DNA	   adducts	   and	   eventually	   DNA	  
mutations	   (2,	  3,	  7,	  10,	  11,	  15-­‐17).	  The	  phase	  2	  xenobiotic	  metabolic	  enzymes	  work	   to	  
counteract	   this	  potential	  effect	  by	  attaching	   large	  polar	  groups	   to	   the	   reactive	   site	  on	  





enzymes	   render	   the	  mutagens	   inert	   and	   allows	   them	   to	   be	   safely	   expelled	   from	   the	  
body.	  	  
A	   common	   phase	   I	   enzyme	   in	   breast	   tissue	   is	   Cyp1B1.	   As	   one	   of	   the	   most	  
abundant	  and	  reactive	  members	  of	  the	  Cytochrome	  P-­‐450	  superfamily	  in	  breast	  tissue,	  
Cyp1B1	  has	  been	  shown	  to	  produce	  much	  higher	  amounts	  of	  carcinogenic	  compounds	  
when	   reacting	  with	   benzopyrene	   derivatives	   and	   estradiol	   (2,	   3,	   13,	   14).	   Four	   cyp1b1	  
gene	  polymorphisms	  have	  found	  that	  alter	  the	  reaction	  rate	  of	  the	  Cyp1B1	  enzyme	  (6,	  
18-­‐26,	   32).	   Each	   of	   the	   four	   polymorphisms	   (142	   C>G,	   355	  G>T,	   4326	   C>G,	   and	   4390	  
A>G)	  result	  in	  amino	  acid	  substitutions	  in	  the	  Cyp1B1	  protein	  (R48G,	  A119S,	  L432V,	  and	  
N453S).	  Due	  to	  their	  effect	  on	  reaction	  rates,	  these	  amino	  acid	  substitutions	  are	  thought	  
to	   increase	  the	  risk	  of	  breast	  cancer	   in	  certain	  populations	   (19,20,27).	  However,	  other	  
investigators	   found	  no	  association	  between	   these	  polymorphisms	  and	  cancer	   risk	   (28-­‐
31).	  The	  difference	  in	  results	  in	  each	  of	  these	  studies	  could	  be	  due	  to	  differences	  in	  race	  
or	  lifestyle	  factors	  of	  these	  populations.	  However,	  the	  observed	  variability	  could	  be	  due	  
to	   a	   small	   effect	   size	   that	   impacts	   only	   certain	   types	   of	   breast	   cancer.	   Therefore,	  
additional	  research	  is	  needed	  to	  elucidate	  the	  role	  of	  cyp1b1	  polymorphisms	  on	  breast	  
cancer	  development.	  Unlike	  the	  previously	  cited	  studies,	  we	  used	  a	  case-­‐case	  approach	  
so	   that	  we	   could	   evaluate	   the	   association	   of	   the	   cyp1b1	  polymorphisms	  with	   specific	  
types	   of	   breast	   tumors	   or	   patient	   characteristics	   to	   determine	   if	   the	   polymorphisms	  





We	   used	   a	   similar	   approach	   in	   the	   analysis	   of	   phase	   II	   xenobiotic	   metabolic	  
enzymes.	   In	  the	  pathway	  of	  xenobiotic	  metabolism,	  phase	   II	  enzymes	  detoxify	   the	  cell	  
through	   conjugation	   reactions.	   Conjugation	   reactions	   involve	   the	   attachment	   of	   large	  
polar	  groups	  to	  the	  reactive	  compounds	  produced	  by	  the	  phase	  I	  enzymes.	  Deviations	  in	  
the	  activity	  or	  amount	  of	  phase	  II	  enzymes	  could	  lead	  to	  an	  accumulation	  of	  mutagenic	  
compounds	  and	  an	  increase	  in	  the	  rate	  of	  mutations	  within	  the	  genome.	  We	  focused	  on	  
two	  phase	   II	   xenobiotic	  metabolic	   enzymes,	  GSTM1	  and	  GSTT1.	  Both	  are	  members	  of	  
the	  glutathione	  S-­‐transferase	  family,	  are	  highly	  expressed	  in	  breast	  tissue,	  and	  deletions	  
of	   each	   gene	   exist	   as	   common	  polymorphisms	   in	   our	   study	   population.	  Many	   studies	  
have	  found	  an	  association	  between	  the	  gstm1	  and	  gstt1	  gene	  deletions	  and	  cancer	  risk	  
(18,	  19,	  36-­‐40).	  However,	  conflicting	  data	  have	  been	  published	  as	  well	  (41-­‐43).	  As	  with	  
cyp1b1,	   racial	   and	   lifestyle	   disparities	   could	   account	   for	   these	   differences,	   and	  
additional	   investigations	   into	   the	   role	   of	   gstm1	   and	   gstt1	   polymorphisms	   in	   breast	  
cancer	   development,	   progression,	   and	   aggressiveness	   are	   necessary.	   Therefore,	   we	  
determined	   patient	   gstm1	   and	   gstt1	   genotypes	   and	   evaluated	   whether	   particular	  
genotypes	   were	   associated	   with	   specific	   types	   of	   breast	   tumors	   or	   patient	  
characteristics.	  
2.2	  Materials	  and	  Methods	  
Polymerase	  Chain	  Reaction	  	  
Sequence	  information	  for	  exon	  2	  and	  exon	  3	  of	  the	  cyp1b1	  gene	  were	  obtained	  





sections	  of	  the	  sequence	  (18-­‐24	  bases)	  were	  selected	  as	  potential	  forward	  and	  reverse	  
primers	   based	   on	   average	   GC	   content	   and	   unique	   nucleotide	   compositions.	   The	  
potential	   primer	   sequences	   were	   analyzed	   for	   Tm,	   self-­‐dimerization,	   hetero-­‐
dimerization,	   and	   hairpin	   formations	   using	   OligoAnalyzer	   software	   (Integrated	   DNA	  
Technologies;	   Coralville,	   Iowa).	   	   Primers	   were	   ordered	   from	   Eurofins	   MWG	   Operon	  
(Forsyth,	  Georgia).	  	  
In	  total,	  601	  patient	  DNA	  samples	  were	  obtained	  from	  the	  South	  Carolina	  Cancer	  
Research	  Repository	  and	  amplified	  for	  sequencing	  of	  cyp1b1	  exon	  2	  and	  exon	  3.	  Since	  
SNPs	  on	  exon	  2	  were	  214	  bases	  apart	  and	  SNPs	  on	  exon	  3	  were	  within	  65	  bases	  of	  each	  
other,	  primers	  for	  each	  exon	  were	  designed	  to	  amplify	  both	  SNPs	  in	  each	  region	  (Table	  
2.1).	  	  
Each	  exon	  2	  amplification	  reaction	  contained	  0.2	  uM	  of	  each	  primer,	  2.5	  mM	  of	  
each	  dNTP,	  1U	  Taq	  DNA	  Polymerase	  (New	  England	  Biolabs;	  Ipswich,	  Massachusetts),	  2.5	  
uL	  of	  ThermoPol	  buffer,	  10	  mg/mL	  BSA,	  2.5	  uL	  of	  99%	  DMSO,	  and	  5	  to	  50	  ng	  of	  genomic	  
DNA.	  The	  amplification	  was	  performed	  with	  an	   initial	  denaturation	  at	  95	  °C	   for	  1	  min,	  
followed	  by	  40	  cycles	  of	  95	  °C	  for	  15	  sec,	  60	  °C	  for	  20	  sec,	  and	  72	  °C	  for	  1	  min.	  The	  final	  
extension	  was	  at	  72	  °C	  for	  7	  min.	  The	  resulting	  amplification	  products	  were	  analyzed	  by	  
agarose	  gel	  electrophoresis	  and	  successful	  amplification	  was	  indicated	  by	  the	  presence	  
of	  a	  914	  bp	  band.	  Exon	  3	  reactions	  contained	  0.2	  uM	  of	  each	  primer,	  2.5	  mM	  of	  each	  
dNTP,	  1U	  Taq	  DNA	  Polymerase	  (New	  England	  Biolabs;	  Ipswich,	  Massachusetts),	  2.5	  uL	  of	  








amplification	  was	  performed	  with	  an	  initial	  denaturation	  at	  95	  °C	  for	  4	  min,	  followed	  by	  
40	  cycles	  of	  95	  °C	  for	  20	  sec,	  54	  °C	  for	  20	  sec,	  and	  72	  °C	  for	  1	  min	  with	  a	  final	  extension	  
of	   5	  min	   at	   72	   °C.	   The	   resulting	   amplification	   products	  were	   analyzed	   by	   agarose	   gel	  
electrophoresis	  and	  successful	  amplification	  was	  indicated	  by	  the	  presence	  of	  a	  652	  bp	  
band.	   The	   amplified	   products	   for	   both	   regions	   were	   kept	   at	   4	   °C	   until	   shipped	   for	  
sequencing.	  	  
gstm1,	  gstt1,	  &	  β-­‐globin	  
	   The	   multiplex	   PCR	   was	   performed	   using	   the	   primers	   listed	   in	   Table	   2.1	   as	  
described	  previously	  by	  Khan	  et	  al.	  (52).	  
Products	  from	  the	  resulting	  multiplex	  PCR	  were	  separated	  through	  electrophoresis	  on	  a	  
1.25%	   agarose	   gel	   and	   stained	   with	   ethidium	   bromide.	   Bands	   were	   visualized	   using	  
ultraviolet	   light.	  Homozygous	  deletions	  of	  the	  gstt1	  and	  gstm1	  gene	  region	  resulted	  in	  
the	  absence	  of	  the	  corresponding	  band	  (gstt1:	  459	  bp,	  gstm1:	  209	  bp)	  (Figure	  2.1).	  The	  
amplification	  of	  the	  β	  globin	  gene	  was	  used	  as	  a	  positive	  control	  for	  the	  multiplex	  PCR	  
reaction.	  
Nucleotide	  Sequencing	  
	   The	   cyp1b1	   exon	   2	   and	   exon	   3	   PCR	   products	   were	   shipped	   to	   the	   High	  
Throughput	   Genomics	   Center	   (Seattle,	   Washington)	   for	   nucleotide	   sequence	  












Figure	  2.1	  Genotype	  Determinations	  of	  GSTM1	  and	  
GSTT1	   through	   Multiplex	   PCR:	   Using	   gstm1,	   gstt1,	  
and	   β-­‐globin	   specific	   primers,	   each	   gene	   was	  
amplified	   via	   multiplex	   PCR.	   The	   resulting	   bands	  
were	   separated	   by	   size	   through	   agarose	   gel	  
electrophoresis.	   Genotypes	   were	   then	   determined	  
by	   reviewing	   banding	   patterns.	   The	   absence	   of	   a	  
band	  at	  459	  bp	  signified	  a	  deletion	  of	  the	  gstt1	  gene	  
(lane	  5).	  The	  absence	  of	  a	  band	  at	  209	  bp	  indicated	  a	  
deletion	  of	  gstm1	  (lanes	  3	  and	  4).	  The	  presence	  of	  a	  
band	   at	   459	   bp	   or	   209	   bp	   signified	   the	   patient	  was	  
either	  heterozygous	  or	  homozygous	  at	  the	  respective	  
locus.	  β-­‐globin	  was	  used	  as	  a	  positive	  control	  for	  the	  






were	  determined	  through	  analysis	  of	  chromatograms	  using	  Sequencher	  5.0	  (Gene	  Codes	  
Corporation;	  Ann	  Arbor,	  Michigan)	  (Figure	  2.2).	  
Statistical	  Analysis	  
Logistic	   regression	   analyses	   was	   performed	   using	   STATA/IC	   10.1	   statistical	  
software	  (StataCorp	  LP;	  College	  Station,	  Texas).	  Associations	  between	  tumor	  or	  patient	  
characteristics	  and	  polymorphisms	  were	  determined	  by	  calculating	  odds	  ratios	  (OR)	  and	  
95%	  confidence	  intervals	  (95%	  CI).	  Significance	  was	  determined	  by	  a	  P-­‐value	  of	  <0.05.	  
2.3	  Results	  and	  Discussion	  
	   In	   examining	  polymorphisms	   in	   the	   cyp1b1,	  gstm1,	   and	  gstt1	  genes,	   a	   total	   of	  
3,436	   genotypes	   were	   determined	   from	   473	   European	   American	   and	   177	   African	  
American	  breast	  cancer	  patients	  (Table	  2.2	  and	  Table	  2.3).	  Allele	  frequencies	  for	  these	  
genes	  were	  found	  to	  be	  in	  Hardy-­‐Weinberg	  equilibrium.	  	  
Cyp1B1	  
	   Over	   the	  years,	  numerous	  polymorphisms	  have	  been	  discovered	   in	   the	  cyp1B1	  
gene	  (54).	  Most	  of	  these	  have	  no	  effect	  on	  the	  enzymatic	  rate	  of	  the	  Cyp1B1	  enzyme.	  
However,	  four	  polymorphisms	  (142	  C>G,	  355	  G>T,	  4326	  C>G,	  and	  4390	  A>G)	  have	  been	  
shown	   to	   increase	   the	   xenobiotic	   metabolic	   rate	   of	   Cyp1B1,	   and	   thus	   increase	   its	  
mutagenic	  potential	  (6,	  18-­‐26,	  32).	  To	  measure	  the	  association	  of	  these	  polymorphisms	  
with	   breast	   cancer	   patient	   and	   tumor	   characteristics,	   DNA	   samples	   were	   taken	   from	  









Figure	   2.2	   Chromatogram	   Analysis	   of	  
Cyp1B1	   Single	   Nucleotide	   Polymorphisms:	  
As	   a	   result	   of	   Sanger	   sequencing,	  
chromatograms	   were	   produced	   displaying	  
levels	  of	  detection	  of	  the	  four	  bases	  at	  each	  
site	   in	   the	   DNA	   sequence.	   The	   genotype	   of	  
each	   SNP	   in	   cyp1b1	   was	   determined	   by	  
analyzing	   peak	   size,	   number,	   and	   color	   at	  
each	  locus.	  1)	  Cyp1b1	  4390	  A:	  Designated	  by	  
the	  single	   large	  green	  peak.	  2)	  Cyp1b1	  4390	  
Heterozygote	   A/G:	   Indicated	   by	   the	   small	  
double	   black	   and	   green	   peaks.	   3)	   Cyp1b1	  







Table	  2.2	  Genotype	   frequencies	  of	   the	  Cytochrome	  P-­‐450	  1B1	  gene	   in	  
Caucasian	  and	  African	  American	  breast	  cancer	  patients.	  
	  	   	  
Cyp1b1	   	  	   	  	   Caucasian	   	  	   African	  American	   Difference	  
Polymorphism	   Genotype	   	  	   N	   %	   	  	   N	   %	   	  
	   	   	   	   	   	   	   	   	   	  
	   	   CC	   	   196	   52.4	   	   43	   28.5	   	  
142	   CG	   	   147	   0.4	   	   70	   46.3	   P<.001	  
	   	   GG	   	   31	   8.3	   	   38	   25.2	   	  
	   	   	   	   	   	   	   	   	   	  
	   	   GG	   	   194	   51.9	   	   51	   33.8	   	  
355	   GT	   	   146	   39.0	   	   69	   45.7	   P<.001	  
	   	   TT	   	   34	   9.1	   	   31	   20.5	   	  
	   	   	   	   	   	   	   	   	   	  
	   	   CC	   	   67	   30.6	   	   11	   9.4	   	  
4326	   CG	   	   106	   48.4	   	   41	   35.0	   P<.001	  
	   	   GG	   	   42	   21.0	   	   65	   55.6	   	  
	   	   	   	   	   	   	   	   	   	  
	   	   AA	   	   156	   71.2	   	   103	   86.6	   	  
4390	   AG	   	   57	   26.0	   	   16	   13.4	   P=.25	  











Table	  2.3	  Genotype	  frequencies	  of	  Glutathione	  S-­‐Transferase	  Mu-­‐1	  and	  






	   	  
	   	   	   	   	   	   	   	  
	  	   	  	   Caucasian	   	  	   African	  American	   Difference	  
	  	   	  	   N	   %	   	  	   N	   %	   	  
GSTM1	   Gene	   	   	   	   	   	   	  
	   Present	   123	   43.3	   	   95	   69.9	   P<.001	  
	   Absent	   161	   56.7	   	   41	   30.1	   	  
	   	   	   	   	   	   	   	  
GSTT1	   Present	   247	   87	   	   108	   79.4	   P=.5	  
	  	   Absent	   37	   13	   	  	   28	   20.6	   	  





able	  to	  determine	  the	  genotype	  of	  the	  aforementioned	  polymorphic	  sites	  and	  assemble	  
the	  individual	  genotypes	  into	  exon-­‐specific	  haplotypes	  of	  the	  patients	  in	  this	  study.	   	  
Haplotype	  determination	  was	  performed	  independently	  for	  the	  exon	  2	  (142	  C>G	  
and	  355	  G>T)	  and	  exon	  3	  (4326	  C>G	  and	  4390	  A>G)	  loci.	  Chromosomes	  that	  contained	  
the	  ancestral	  allele	  at	  both	  of	  the	  polymorphic	  sites	  of	  exon	  2	  were	  considered	  to	  have	  
haplotype	  A.	   Therefore,	   individuals	  who	  were	  homozygous	   for	   the	   ancestral	   alleles	   at	  
both	  polymorphic	  sites	  had	  an	  AA	  genotype.	  Similarly,	  if	  an	  individual	  was	  homozygous	  
for	   the	  derived	  alleles	  at	  both	   loci,	   she	  would	  have	  a	  BB	  genotype.	  Alternatively,	   if	  an	  
individual	  was	  heterozygous	  at	   the	  142	  C>G	   locus	  and	  homozygous	  for	  haplotype	  A	  at	  
the	  355	  G>T	  locus,	  her	  genotype	  would	  be	  AC	  (Figure	  2.3).	  This	  approach	  allowed	  us	  to	  
determine	  the	  haplotypic	  genotypes	  of	  62%	  of	  the	  women	  with	  allelic	  determinations	  at	  
cyp1B1	   exon	   2.	   The	   remaining	   women	   were	   heterozygous	   at	   both	   loci.	   For	   these	  
individuals,	   it	   is	   not	   obvious	   whether	   the	   two	   ancestral	   alleles	   are	   on	   the	   same	  
chromosome	   or	   one	   is	   located	   on	   each	   chromosome.	   However,	   since	   only	   1%	   of	   the	  
identified	   haplotypes	   contained	   the	   ancestral	   allele	   at	   the	   142	   C>G	   locus	   and	   the	  
derived	  allele	  at	  the	  355	  G>T	  locus,	  we	  assumed	  that	  this	  potential	  haplotype	  was	  rare	  
enough	   to	   not	   affect	   statistical	   significance.	   	   Therefore,	   we	   were	   able	   to	   assign	   the	  
haplotypes	   of	   the	   cyp1b1	   gene	   in	   doubly	   heterozygous	   individuals	   by	   excluding	   the	  
haplotype	   combinations	   that	   required	   the	   rare	   haplotype.	   A	   similar	   approach	   was	  
successful	   for	   identifying	   the	   haplotypes	   present	   in	   exon	   3	   of	   the	   cyp1b1	   gene.	   To	  
measure	   statistical	   associations,	   logistic	   regression	   analysis	   was	   used	   to	   compare	   the	  






Figure	   2.3	   Determination	   of	   cyp1b1	   haplotypes	   and	   genotypes	   in	   African	   American	  
and	   European	   American	   breast	   cancer	   patients.	   Haplotypes	   were	   assigned	   first	   for	  
patients	  who	  were	  determined	   to	   be	   at	   least	   homozygous	   at	   one	  of	   the	   polymorphic	  
sites	   in	  exon	  2	  or	  exon	  3.	   In	  each	  of	  the	  groups	  analyzed	  one	  potential	  haplotype	  was	  
found	  to	  be	  absent	  or	  only	  present	  in	  1%	  of	  the	  population.	  We	  were	  therefore	  able	  to	  
determine	  the	  haplotype	  of	  individuals	  who	  were	  heterozygous	  at	  each	  locus	  in	  exon	  2	  






2.4,	  2.5	  and	  2.6.	  No	  significant	  associations	  were	  discovered	  between	  any	  of	  the	  cyp1b1	  
genotypes	   and	   any	   of	   the	   13	   African	   American	   or	   Caucasian	   breast	   cancer	   patient	   or	  
tumor	   characteristics.	   These	   results	   are	   consistent	   with	   previous	   studies,	   which	   have	  
also	  failed	  to	  find	  an	  association	  between	  polymorphisms	  in	  the	  cyp1b1	  gene	  and	  breast	  
cancer	   susceptibility	   (28-­‐31).	   As	   previously	   mentioned,	   Cyp1b1	   has	   been	   shown	   to	  
produce	   mutagenic	   metabolites	   and	   these	   four	   polymorphisms	   have	   experimentally	  
demonstrated	   the	   ability	   to	   increase	   both	   the	   enzymatic	   rate	   and	   the	   mutagenic	  
potential	   of	   the	   Cyp1b1	   enzyme.	   Previous	   studies	   have	   shown	   that	   an	   increased	  
mutation	  rate	  leads	  to	  increased	  breast	  cancer	  risk	  (50,	  51,	  55).	  However,	  it	  is	  plausible	  
that	  an	  increase	  in	  phase	  I	  xenobiotic	  metabolic	  pathway	  products	  could	  induce	  phase	  II	  
xenobiotic	  enzymes.	  This	  phase	  II	   induction	  would	  limit	  or	  nullify	  the	  effects	  of	  cyp1b1	  
polymorphisms.	  Alternatively,	  over	  the	  course	  of	  their	  lifetime,	  the	  patients	  in	  our	  study	  
may	  have	  experienced	  different	  levels	  of	  xenobiotic	  compounds	  or	  hormones	  such	  that	  
the	   presence	   of	   cyp1b1	   polymorphisms	   does	   not	   correlate	   with	   mutation	   rates.	  
Furthermore,	   it	   is	  possible	  that	  the	  cyp1b1	  polymorphisms	  have	  only	  a	  small	  effect	  on	  
breast	  cancer	  progression	  and	  aggressiveness.	  Thus,	   this	  study	  may	   lack	  the	  necessary	  
sample	  size	  to	  detect	  those	  associations.	  	  
GSTM1	  and	  GSTT1	  
As	  phase	  II	  xenobiotic	  metabolizing	  enzymes,	  the	  glutathione	  S-­‐transferase	  family	  works	  
to	   detoxify	   the	   cell	   by	   adding	   a	   large	   polar	   molecule	   to	   the	   toxic	   or	   carcinogenic	  
hydrophobic	   substances	   produced	   from	   the	   phase	   I	   enzymes.	   It	   is	   believed	   that
	  
	  














Table	  2.6	  Distribution	  of	  African	  American	  and	  Caucasian	  





	   	  
	  	   	  	   	  	   Caucasian	   African	  American	  
Age	  at	  Diagnosis	   	  	   n=452	   n=168	  
	   Mean	  ±	  SD	   56.2	   ±11.5	   51.7	   ±11.67	  





decreased	  levels	  of	  phase	  II	  enzymes	  would	  increase	  the	  level	  of	  carcinogenic	  material	  in	  
the	   cell	   and	   lead	   to	   an	   increase	   in	   mutations,	   thus	   potentially	   leading	   to	   the	  
development	  of	  cancer.	  	  Therefore,	  we	  looked	  at	  two	  gene	  deletion	  polymorphisms	  that	  
have	  previously	  been	  associated	  with	  the	  development	  of	  different	  cancers	  (18,	  19,	  36-­‐
40).	   By	   utilizing	  multiplex	   PCR	  with	   primers	   complementary	   to	  DNA	   sequences	  within	  
the	   gstt1	   and	   gstm1	   genes,	   we	   were	   able	   to	   amplify	   the	   respective	   genes	   in	   the	  
genomes	   that	   contained	   at	   least	   one	   copy.	   However,	   because	   this	   technique	   only	  
detects	  the	  presence	  or	  absence	  of	  the	  glutathione	  s-­‐transferase	  genes	  we	  are	  unable	  to	  
detect	  the	  genomes	  that	  are	  heterozygous	  for	  either	  or	  both	  genes	  (figure	  2.4).	  Our	  data	  
indicated	  that	  the	  two	  glutathione	  S-­‐transferase	  genes,	  gstm1	  and	  gstt1,	  are	  absent	   in	  
57%	   and	   13%	   in	   the	   European	   American	   population	   30%	   and	   21%	   in	   the	   African	  
American	  population,	  respectively.	  Homozygous	  deletions	   in	  both	  the	  gstm1	  and	  gstt1	  
genes	  were	  present	  in	  only	  6.3%	  of	  European	  Americans	  and	  5.8%	  of	  African	  Americans.	  
To	  assess	  possible	  associations	  between	  the	  gstm1	  and	  gstt1	  gene	  deletions	  with	  breast	  
cancer	   patient	   and	   tumor	   characteristics	   (Tables	   2.4	   and	   2.5),	   we	   used	   logistic	  
regression.	  No	  significant	  associations	  were	  found	  between	  gstt1,	  gstm1,	  or	  the	  gstm1-­‐
gstt1	  double	  deletion	  genotypes	  and	  any	  of	   the	  African	  American	  or	  Caucasian	  breast	  
cancer	   patient	   or	   tumor	   characteristics.	   Products	   from	  phase	   I	   xenobiotic	  metabolism	  
can	   lead	   to	   the	   development	   of	   cancer,	   and	   enzymes	   in	   phase	   II	   of	   the	   xenobiotic	  
metabolic	  pathway	  are	  able	  to	  deactivate	  many	  of	  these	  carcinogens	  (2,	  3,	  7,	  10,	  11,	  15-­‐
17).	   However,	   with	   high	   substrate	   overlap	  within	   classes	   of	   glutathione	   S-­‐transferase	  











Figure	  2.4	  Representative	  results	  for	  GSTT1	  and	  GSTM1	  multiplex	  PCR:	  Figure	  shows	  a	  
representative	  gel	  for	  the	  amplification	  of	  β-globin, gstt1	  and	  gstm1	  through	  multiplex	  
PCR.	   GSTT1	   and	   GSTM1	   genotypes	   are	   signified	   by	   a	   “+”	   for	   presence	   and	   a	   “-­‐“	   for	  
absence.	  No	  results	  were	  gathered	   from	   lanes	  8	  and	  9	  as	  positive	  control	  Beta	  Globin	  









reduced	   by	   increased	   expression	   or	   activity	   of	   other	   mu	   or	   theta	   class	   genes.	   Thus,	  
further	  investigation	  into	  the	  expression	  levels	  of	  glutathione	  S-­‐transferase	  mu	  class	  and	  
glutathione	   S-­‐transferase	   theta	   class	   genes	   in	   gstm1	   and	   gstt1	   null	   patients	   is	  
warranted.	  Alternatively,	  as	  with	  cyp1b1,	   lifetime	  exposure	  of	   xenobiotics	  may	   impact	  
the	   effect	   of	   the	   gstm1	   or	   gstt1	   null	   genotype	   of	   breast	   cancer.	   Also,	   the	   impact	   of	  
polymorphisms	   in	   the	   gstm1	   or	   gstt1	   genes	   on	   breast	   cancer	   patient	   and	   tumor	  
characteristics	  may	  be	  too	  small	   for	  our	  analysis	  to	  accurately	  detect.	  Previous	  studies	  
have	   reported	   that	   the	   aforementioned	   cyp1b1	   polymorphisms	   lead	   to	   increased	  
carcinogen	  production	  and	  mutation	  rate.	  The	  effects	  of	  these	  polymorphisms	  on	  breast	  
cancer	  may	  be	  exacerbated	  in	  patients	  with	  deletions	  in	  gstm1	  and	  gstt1	  genes,	  as	  they	  
have	  reduced	  phase	   II	  xenobiotic	  metabolic	  enzymatic	  capacity.	  Once	  again,	  our	  study	  
lacked	  sufficient	  power	  to	  analyze	  this	  hypothesis	  since	  these	  patients	  would	  represent	  
only	  a	  small	  percentage	  of	  the	  population.	  	  
In	   summation,	   while	   this	   study	   failed	   to	   show	   any	   significant	   associations	  
between	  polymorphisms	  in	  the	  cyp1b1,	  gstm1,	  or	  gstt1	  genes	  and	  breast	  cancer	  patient	  
or	   tumor	   characteristics,	   we	   cannot	   rule	   out	   a	   small	   effect	   on	   breast	   cancer	  
development	  or	  progression.	  An	  increase	  in	  sample	  size	  and	  comparison	  of	  phase	  I	  and	  
phase	  II	  polymorphisms	  with	  factors	  such	  as	  xenobiotic	  exposure	  could	  help	  to	  identify	  
previously	   undetected	   associations.	   Furthermore,	   studies	   into	   phase	   II	   xenobiotic	  
metabolic	  gene	  expression	  will	  help	  to	  elucidate	  how	  the	  cell	  compensates	  for	  varying	  







CHAPTER	  3:	  AMINO	  ACID	  SUBSTITUTIONS	  CAUSE	  MODEST	  EFFECT	  ON	  CYP1B1	  PROTEIN	  STABILITY	  






	   Cytochrome	  P450	  Family	  1	  Subfamily	  B	  Protein	  1	  (CYP1B1)	  plays	  a	  fundamental	  
role	   in	   the	  metabolism	  of	  numerous	  mutagenic	  and	  toxic	  xenobiotics.	   In	   reacting	  with	  
these	   xenobiotic	   substrates,	   Cyp1B1	  often	   increases	   their	  mutagenic	   and	   carcinogenic	  
potential.	   We	   examined	   the	   effect	   of	   four	   single	   nucleotide	   polymorphisms	   in	   the	  
Cyp1b1	   gene,	   which	   lead	   to	   amino	   acid	   substitutions,	   on	   Cyp1B1	   protein	   stability.	  
Stability	   of	   the	   endogenous	   Cyp1B1	   in	   human	   cell	   lines	   was	   measured	   utilizing	  
cycloheximide	  chase	  and	  western	  blotting	   techniques.	  Our	  data	   indicated	  a	   significant	  
20%	  decrease	  (p:	  0.042)	   in	  the	  half-­‐life	  of	  Cyp1B1*4	  (Asparagine	  to	  Serine	  substitution	  
at	   amino	   acid	   position	   453)	   compared	   to	   Cyp1B1*3	   (Leucine	   to	  Valine	   substitution	   at	  
amino	  acid	  position	  432).	  We	  also	  noticed	  a	  significant	  50%	  increase	  (p:0.03)	  in	  the	  half-­‐
life	  of	  Cyp1B1*2	  (Arginine	  to	  Glycine	  substitution	  at	  amino	  acid	  position	  48	  and	  Alanine	  
to	  Serine	  substitution	  at	  amino	  acid	  position	  119)	  compared	  to	  Cyp1B1*3.	  Utilizing	  the	  
proteasome	   inhibitor	  MG132	   in	  conjunction	  with	   the	  cycloheximide	  chase	   techniques,	  
we	   verified	   that	  Cyp1B1	   is	   degraded	   through	   the	  proteasomal	  pathway.	  Compared	   to	  
previous	   findings,	   our	   results	   show	   conservative	   changes	   in	   degradation	   rates,	   and	   as	  
such	  we	  hypothesize	  that	  differences	  in	  half-­‐life	  for	  the	  Cyp1B1	  variants	  have	  little	  to	  no	  
effect	  on	  the	  production	  of	  carcinogenic	  compounds	  and	  thus	  cancer	  development	  and	  
progression.	  






	   Xenobiotic	   metabolizing	   enzymes	   play	   an	   important	   role	   in	   purifying	   the	   cell	  
from	  potential	   toxic	   and	   carcinogenic	  materials.	   To	  perform	   this	   function,	   enzymes	  of	  
the	   phase	   I	   and	   phase	   II	   xenobiotic	   metabolic	   pathway	   must	   convert	   hydrophobic	  
substrates	  into	  polar	  hydrophilic	  products.	  Often	  during	  the	  phase	  I	  modifications	  these	  
toxic	  substrates	  are	  converted	  to	  highly	  mutagenic	  compounds.	  Thus	  mutations	   in	   the	  
phase	   I	   metabolizing	   genes,	   which	   lead	   to	   amino	   acid	   substitutions,	   can	   cause	   an	  
alteration	  in	  the	  functionality	  of	  these	  proteins	  and	  variation	  in	  carcinogenic	  production.	  
	   As	   a	   member	   of	   the	   largest	   family	   of	   proteins	   in	   the	   xenobiotic	   metabolizing	  
pathway,	  and	  as	  one	  of	  the	  highest	  expressed	  xenobiotic	  metabolizing	  pathway	  phase	  I	  
proteins,	  we	  chose	  to	  study	  Cyp1B1.	  Previous	  studies	  have	  examined	  the	  effects	  of	  four	  
mutations	   in	   exon	   2	   and	   exon	   3	   of	   the	   cyp1b1	   gene,	   which	   lead	   to	   amino	   acid	  
substitutions	  (figure	  1.6)	  (3,	  6,	  18-­‐27,	  32).	  Shimada	  et	  al.	  reported	  an	  increase	  in	  the	  rate	  
of	  metabolism	  of	  benzopyrene	  derivatives	  in	  mutants	  that	  contained	  a	  Serine	  residue	  at	  
position	  119	   instead	  of	   the	   ancestral	  Alanine	   (23).	   In	   contrast,	  Aklillu	  et	   al.	   found	   the	  
formation	   of	   benzopyrene	   derivatives	   to	   be	   decreased	   in	   Cyp1b1	   proteins	   with	   an	  
Asparagine	  to	  Serine	  amino	  acid	  substitution	  at	  453	  (22).	  	  In	  addition,	  Shimada	  et	  al.	  also	  
showed	   that	  amino	  acid	   substitutions	  at	  positions	  432	  and	  432+119	  yielded	   increased	  
production	  of	  4-­‐hydroxyestradiol,	  a	  known	  carcinogen,	  and	  	  Aklillu	  et	  al.	  showed	  that	  a	  
Serine	  substitution	  at	  position	  453	  of	  Cyp1B1	   lead	  to	  a	  decrease	   in	  4-­‐hydroxyestradiol	  





hydroxyestradiol	   production	   in	   Cyp1B1	   Serine	   453	   variants.	   It	   was	   also	   shown	   that	  
Serine	  119	  variants	  had	  a	  3.4	  fold	  increase	  in	  4-­‐hydroxyestradiol.	  Other	  Cyp1B1	  variants	  
proved	  to	  have	  little	  effect	  on	  Km	  or	  Vmax	  in	  relation	  to	  benzopyrene	  or	  estrogen	  catalysis	  
(3,	   6,	   21-­‐23,	   32).	   It	   is	   clear	   that	   changes	   in	   the	   amino	   acid	   sequence	   of	   Cyp1B1	   have	  
varying	  effects	  on	   the	   catalysis	  of	   specific	   substrates;	  however	   few	   studies	  have	  been	  
performed	   to	   analyze	   the	   effect	   of	   amino	   acid	   sequence	   changes	   on	   Cyp1B1	   protein	  
stability.	  	  
	   Previously,	  Ingleman-­‐Sundberg	  et	  al.	   	  and	  Bandiera	  et	  al.	  examined	  the	  stability	  
of	   the	   Cyp1b1*2	   (Glycine	   48,	   Serine	   119)	   and	   Cyp1b1*4	   (Serine	   453)	   variant	   proteins	  
through	   overexpression	   in	   COS-­‐1	   African	   Green	   Monkey	   cells	   (21,	   44).	   In	   these	  
experiments,	   it	  was	  shown	  that	  Cyp1b1*4	  was	  degraded	  more	  than	  three	  times	  faster	  
than	   the	   ancestral	   protein	   (5	   hrs.	   Cyp1b1*4,	   17hrs	   Cyp1b1*1),	   whereas	   Cyp1b1*2	  
displayed	   no	   significant	   difference	   in	   stability	   from	   that	   of	   the	   ancestral	   protein.	  	  
However,	   these	   results	  may	   not	   reflect	   the	   rates	   of	   degradation	   that	   occur	   in	   human	  
cells	  with	  endogenous	  rates	  of	  protein	  expression.	  	  
Through	  the	  use	  of	  predictive	  software	  (NetPhos	  2.0	  and	  GPS	  2.1),	  we	  found	  that	  
Serine	  substitutions	  at	  positions	  119	  and	  453	  generate	  potential	  phosphorylation	  sites	  
at	   119	   and	   458,	   respectively	   (figure	   1.7).	   These	   additional	   phosphorylation	   sites	  may	  
result	   in	   the	   formation	  of	  a	  phosphodegron,	  a	  pattern	  of	  phosphorylated	  amino	  acids	  
used	  to	  identify	  proteins	  for	  ubiquitination	  and	  eventually	  degradation.	  In	  this	  pathway,	  





recognition	  sites	  for	  the	  E3	  ubiquitin	  ligase.	  It	  is	  our	  hypothesis	  that	  the	  Cyp1B1	  protein	  
will	   be	   phosphorylated	   at	   the	   119	   and	   458	   phosphorylation	   sites	   in	   addition	   to	   the	  
normal	   phosphorylation	   sites	   when	   the	   additional	   serine	   residues	   are	   present	   (figure	  
1.7).	  The	  proximity	  of	  these	  phosphate	  groups	  to	  each	  other	  would	  cause	  E3	  ubiquitin	  
ligase	  to	  recognize	  and	  bind	  Cyp1B1	  more	  efficiently	  as	  a	  substrate.	  Once	  bound,	  E3	  will	  
transfer	  ubiquitin	  tags	  to	  the	  phosphorylated	  Cyp1B1	  (Figure	  1.8),	  which	  will	  direct	  the	  
protein	  to	  the	  proteasome	  for	  degradation.	  To	  study	  the	  effects	  of	  these	  mutations	  on	  
the	  degradation	  rate	  of	  Cyp1B1,	  we	  analyzed	  the	  endogenous	  Cyp1B1	  protein	  in	  three	  
different	  human	  cell	  lines	  and	  found	  that	  the	  presence	  of	  the	  serine	  residues	  had	  only	  a	  
small	   impact	   on	   Cyp1B1	   degradation	   rates	   (Table	   3.1).	   Thus,	   overexpression	   of	   the	  
Cyp1B1*4	  protein	  in	  African	  Green	  Monkey	  cells	  apparently	  led	  to	  exaggerated	  rates	  of	  
degradation.	  
3.2	  Materials	  and	  Methods	  
Cell	  Line	  and	  Reagents	  
	   BT20,	  T47D,	  and	  MCF7	  cell	  lines	  were	  donated	  by	  the	  Pittman	  Laboratory	  (South	  
Carolina	  College	  of	  Pharmacy).	  All	   cell	   lines	  were	  maintained	  at	  37.5°C	  and	  5%	  CO2	   in	  
Dulbecco’s	   modified	   Eagle’s	   medium	   (DMEM)	   (Corning	   Cellgro,	   Manassas,	   VA)	  
supplemented	   with	   10%	   new-­‐born	   calf	   serum,	   1%	   penicillin/streptomycin	   (Thermo	  














Table	  3.1	  Cyp1b1	  Variants	  Present	  in	  BT20,	  MCF7,	  and	  T47D	  Breast	  Cancer	  Cell	  Lines:	  	  
The	  T47D	  cell	  line	  has	  amino	  acid	  substitutions	  at	  locations	  48	  and	  119.	  BT20	  is	  used	  as	  
the	   ancestral	   equivalent	   with	   an	   amino	   acid	   substitution	   at	   location	   432.	   It	   was	  
previously	  determined	   that	   a	  mutation	   at	   location	  432	  had	  no	  effect	   on	  degradation	  
rates	  (44).	  MCF7	  has	  a	  Serine	  substitution	  at	  location	  453.	  	   	  










T47D	   Mutant	   Mutant	   WT	   WT	   Cyp1B1*2	  
BT20	   WT	   WT	   Mutant	   WT	   Cyp1B1*3	  





Genotyping	  Cell	  Lines	  
Sequence	   information	  for	  exon	  2	  and	  exon	  3	  of	   the	  cyp1b1	  gene	  was	  obtained	  
from	   the	   National	   Center	   for	   Biotechnology	   Information	   (NCBI)	   SNP	   database.	   Since	  
SNPs	  on	  exon	  2	  were	  214	  bases	  apart	  and	  SNPs	  on	  exon	  3	  were	  within	  65	  bases	  of	  each	  
other,	  primers	  for	  each	  exon	  were	  designed	  to	  amplify	  both	  SNPs	  in	  each	  region	  (Table	  
3.2)	   Small	   sections	   of	   the	   sequence	   (18-­‐24	   bases)	  were	   selected	   as	   potential	   forward	  
and	  reverse	  primers	  based	  on	  average	  GC	  content	  and	  unique	  nucleotide	  compositions.	  
The	   potential	   primer	   sequences	   were	   analyzed	   for	   Tm,	   self-­‐dimerization,	   hetero-­‐
dimerization,	   and	   hairpin	   formations	   using	   OligoAnalyzer	   software	   (Integrated	   DNA	  
Technologies;	   Coralville,	   Iowa).	   	   Primers	   were	   ordered	   from	   Eurofins	   MWG	   Operon	  
(Forsyth,	  Georgia.	  	  
Each	  exon	  2	  amplification	  reaction	  contained	  0.2	  uM	  of	  each	  primer,	  2.5	  mM	  of	  
each	  dNTP,	  1U	  Taq	  DNA	  Polymerase	  (New	  England	  Biolabs;	  Ipswich,	  Massachusetts),	  2.5	  
uL	  of	  ThermoPol	  buffer,	  10	  mg/mL	  BSA,	  2.5	  uL	  of	  99%	  DMSO,	  and	  5	  to	  50	  ng	  of	  genomic	  
DNA.	  The	  amplification	  was	  performed	  with	  an	   initial	  denaturation	  at	  95	  °C	   for	  1	  min,	  
followed	  by	  40	  cycles	  of	  95	  °C	  for	  15	  sec,	  60	  °C	  for	  20	  sec,	  and	  72	  °C	  for	  1	  min.	  The	  final	  
extension	  was	  at	  72	  °C	  for	  7	  min.	  The	  resulting	  amplification	  products	  were	  analyzed	  by	  
agarose	  gel	  electrophoresis	  and	  successful	  amplification	  was	  indicated	  by	  the	  presence	  
of	  a	  914	  bp	  band.	  	  
Exon	  3	  reactions	  contained	  0.2	  uM	  of	  each	  primer,	  2.5	  mM	  of	  each	  dNTP,	  1U	  Taq	  








buffer,	  10	  mg/mL	  BSA,	  25	  mM	  MgCl2,	  and	  5	  to	  50	  ng	  of	  genomic	  DNA.	  The	  amplification	  
was	  performed	  with	  an	  initial	  denaturation	  at	  95	  °C	  for	  4	  min,	  followed	  by	  40	  cycles	  of	  
95	  °C	  for	  20	  sec,	  54	  °C	  for	  20	  sec,	  and	  72	  °C	  for	  1	  min	  with	  a	  final	  extension	  of	  5	  min	  at	  
72	  °C.	  The	  resulting	  amplification	  products	  were	  analyzed	  by	  agarose	  gel	  electrophoresis	  
and	  successful	  amplification	  was	  indicated	  by	  the	  presence	  of	  a	  652	  bp	  band.	  The	  
amplified	  products	  for	  both	  regions	  were	  kept	  at	  4	  °C	  until	  they	  were	  shipped	  to	  High	  
Throughput	  Genomics	  Center	  (Seattle,	  WA)	  for	  nucleotide	  sequence	  identification.	  	  
	   	  Genotypes	   were	   determined	   through	   analysis	   of	   chromatograms	   using	  
Sequencher	  5.0	  (Gene	  Codes	  Corporation;	  Ann	  Arbor,	  Michigan).	  
Determination	  of	  Cyp1B1	  stability	  
Once	  cells	  were	  grown	  to	  confluence	  in	  primary	  growth	  medium,	  200	  µg/mL	  of	  
the	  protein	  synthesis	  inhibitor	  cycloheximide	  (CHX)	  was	  added	  to	  stop	  protein	  synthesis.	  	  
Cells	  were	  harvested	  from	  the	  plates	  and	  lysed	  using	  cold	  lysis	  buffer	  at	  0,	  4,	  and	  8	  hours	  
after	  CHX	  addition.	  Protein	  concentrations	  were	  determined	  using	  the	  Bio-­‐Rad	  Protein	  
Assay	   (Bio-­‐Rad,	   Hercules,	   CA).	   Equal	   amounts	   of	   protein	   were	   subjected	   to	   SDS-­‐
polyacrylamide	  gel	  electrophoresis	  (PAGE)	  and	  transferred	  to	  nitrocellulose	  membranes	  
using	   an	   electroblot	   process	   (Bio-­‐Rad,	  Hercules,	   CA).	   The	   resulting	   blots	  were	   stained	  
with	  Ponceau	  S	   (Sigma,	  St.	   Louis,	  MO)	  as	  described	  by	  Romero-­‐Calvo	  et	  al.	   (58).	  After	  
staining,	  the	  blots	  were	  incubated	  with	  50	  mg/ml	  of	  BSA	  for	  1	  hour	  (AMRESCO,	  Solon,	  
OH),	  and	   the	  BSA-­‐coated	  blots	  were	   incubated	  at	  4°C	  overnight	  using	   the	  appropriate	  




following	   day,	   the	   blots	   were	   washed	   for	   15	   minutes	   and	   incubated	   with	   secondary	  
antibody	   for	   1	   hr	   (Anti-­‐rabbit	   igG:	   A2556,	   Sigma,	   St.	   Louis,	  MO).	   Following	   secondary	  
antibody	   incubation,	   Lumi-­‐Phos	   chemiluminescent	   substrate	   (Thermo-­‐Scientific,	  
Waltham,	   MA)	   was	   used	   with	   HyBlot	   autoradiography	   film	   to	   detect	   protein	   bands.	  
Mean	   band	   intensity	   was	   measured	   to	   quantify	   degradation	   of	   Cyp1B1	   using	   Adobe	  
Photoshop.	  	  
	   To	  confirm	   that	   the	  proteasome	  was	   responsible	   for	  Cyp1B1	  degradation,	   cells	  
were	   grown	   to	   confluence	   in	   primary	   growth	   medium	   and	   then	   200	   µg/mL	   of	   the	  
protein	   synthesis	   inhibitor	   cycloheximide	   (CHX)	   and	   20µM	   of	   proteasome	   inhibitor	  
MG132	  was	  added.	  Cells	  were	  harvested	  and	  analyzed	  as	  described	  above.	  	  
Statistical	  Analysis	   	  	  
	   	  Experiments	   were	   performed	   in	   triplicate,	   and	   Z-­‐score	   analysis	   was	   used	   to	  
asses	  statistical	  significance	  of	  Cyp1B1	  half-­‐life.	  	  
3.3	  Results	  and	  Discussion	  
	   Over	  the	  past	  two	  decades,	  numerous	  studies	  have	  examined	  the	  effect	  of	  four	  
specific	   Cyp1B1	   polymorphisms	   and	   their	   relation	   to	   xenobiotic	   catalysis	   and	   cancer	  
(Figure	  3.1)	  (3,	  6,	  18-­‐27,	  32).	  In	  more	  recent	  years,	  two	  studies	  investigated	  the	  role	  of	  
these	   polymorphisms	   on	   protein	   stability	   (21,	   44).	   However,	   as	   the	   these	   Cyp1B1	  
protein	   stability	   studies	   were	   conducted	   using	   overexpression	   techniques	   in	   African	  








Figure	   3.1	   Polymorphisms	   in	   the	   Cyp1B1	   gene	   and	  
protein:	   The	   relative	   positions	   of	   four	   polymorphisms	  
found	   in	   the	   Cyp1B1	   gene,	   which	   yield	   amino	   acid	  
substitutions.	  A)	   142	   C>G	   causes	   an	   Arginine	   to	   Glycine	  
change	  at	  amino	  acid	  number	  amino	  acid	  number	  48.	  355	  
G>T	   causes	   an	   Alanine	   to	   Serine	   change	   at	   amino	   acid	  
number	  119.	  4326	  C>G	  causes	  a	  Leucine	  to	  Valine	  change	  
at	   amino	   acid	   number	   432.	   4390	   A>G	   causes	   an	  








in	  human	  cell	  lines	  utilizing	  the	  endogenous	  Cyp1B1	  proteins	  to	  obtain	  a	  more	  accurate	  
estimation	   of	   the	   impact	   of	   Cyp1b1	   polymorphisms	   on	   Cyp1b1	   protein	   stability.	   To	  
determine	  Cyp1B1	  protein	  stability,	  cell	  lines	  were	  selected	  based	  on	  Cyp1B1	  genotype	  
homozygosity	   and	   their	   relation	   to	   breast	   cancer.	   Nucleotide	   sequencing	   of	   cell	   line	  
genomic	  DNA	  determined	  that	  the	  BT20	  cell	   line	  had	  a	  polymorphism	  at	  position	  4326	  
corresponding	   to	   an	   amino	   acid	   substitution	   (valine	  àleucine)	   at	   position	   432.	   It	   has	  
been	   shown	   previously	   that	   this	   mutation	   has	   no	   effect	   on	   degradation	   (44),	   and	  
predictive	  data	  indicated	  no	  mechanism	  for	  altered	  degradation	  rate.	  Similarly,	  the	  T47D	  
cell	  line	  was	  shown	  to	  contain	  a	  polymorphism	  at	  positions	  142	  and	  355,	  which	  leads	  to	  
amino	  acid	  substitutions	  at	  positions	  48	  (arginineà	  glycine)	  and	  119	  (alanineàserine).	  
Genotyping	   of	   the	   MCF7	   cell	   line	   revealed	   a	   polymorphism	   at	   site	   4390	   yielding	   an	  
amino	  acid	   substitution	   at	   453	   (asparagineàserine).	   Predictive	   software	   (NetPhos	  2.0	  
and	  GPS	  2.1)	  indicated	  amino	  acid	  substitutions	  at	  position	  119	  and	  position	  453	  lead	  to	  
increased	   phosphorylation	   (Figure	   1.7).	   	   To	   determine	   if	   these	   phosphorylation	   sites	  
lead	  to	  a	  change	  in	  rates	  of	  Cyp1B1	  degradation,	  we	  grew	  T47D,	  BT20,	  and	  MCF7	  cells	  
(Cyp1B1*2,	  Cyp1B1*3,	  and	  Cyp1B1*,	  respectively)	   in	  the	  presence	  of	  cycloheximide	  to	  
stop	  protein	  synthesis	  and	  measured	  the	  loss	  of	  Cyp1b1	  protein	  over	  the	  course	  of	  eight	  
hours	  using	  western	  blotting	  techniques	  (Table	  3.1).	  Since	  Cyp1A1	   is	  homologous	  with	  
Cyp1B1,	  Cyp1A1	  was	  used	  as	  a	  control	  to	  detect	  possible	  cell	   line	  differences	  affecting	  
protein	   degradation.	   Using	   Cyp1B1*3	   as	   reference	   and	   normalizing	   with	   Cyp1A1	  
degradation	   levels,	   we	   found	   significant	   variation	   among	   the	   half-­‐lives	   of	   Cyp1B1*2,	  








Figure	   3.2	   Cyp1B1	   degradation	   Relative	   degradation	   rates	   of	   Cyp1B1	  
variants	  using	  cycloheximide	  chase	  from	  0	  to	  8	  hours.	  Cyp1B1*3	  was	  used	  
as	  the	  ancestral	  version	  of	  the	  gene.	  Cyp1B1*4	  showed	  an	  increased	  rate	  of	  
degradation	  and	  a	  half-­‐life	  of	  13	  hrs.	  Cyp1B1*2	  demonstrated	  a	  decreased	  
rate	  of	  degradation	  and	  a	  half-­‐life	  of	  24	  hrs.	  Cyp1B1*3	  was	  determined	  to	  
have	  a	  half-­‐life	  of	  16	  hrs.	  #	  signifies	  significance.	  




found	  that	  Cyp1B1*4	  had	  a	  decreased	  half-­‐life	  compared	  to	  that	  of	  Cyp1B1*3.	  However,	  
our	  data	  depicts	  Cyp1B1*4	  degrading	  at	  a	  rate	  that	  is	  more	  than	  2.5	  times	  slower	  than	  
that	  detected	  by	  Bandiera	  et	  al.	  (44).	  This	  difference	  in	  Cyp1B1*4	  degradation	  rates	  may	  
be	   due	   to	   differences	   between	   human	   and	  monkey	   cells	   or	   the	   fact	   that	   the	   human	  
Cyp1B1*4	   is	   a	   foreign	   protein	   in	   the	   monkey	   cells.	   Furthermore,	   overexpression	   of	  
Cyp1B1*4	   leads	   to	   a	   non-­‐natural	   state,	   which	   could	   potentially	   alter	   the	   detectable	  
rates	  of	  degradation.	  
The	  increased	  rate	  of	  Cyp1B1*4	  degradation	  is	  probably	  due	  to	  creation	  of	  a	  new	  
phosphorylation	  site	  in	  the	  Cyp1B1*4	  variant	  protein	  by	  the	  Asparagine	  to	  Serine	  amino	  
acid	  substitution	  at	  amino	  acid	  number	  453.	  We	  hypothesize	  that	  this	  phosphorylation	  
leads	  to	  the	  formation	  of	  a	  phosphodegron	  which	  would	  target	  the	  Cyp1B1*4	  protein	  to	  
the	  proteasome	  for	  degradation	  and	  increase	  the	  rate	  of	  Cyp1B1*4	  turnover.	  	  
In	   addition	   to	   the	   Cyp1B1*4	   data,	   we	   also	   found	   a	   significant	   difference	   in	  
Cyp1B1*2	  (24	  hours)	  degradation	  compared	  to	  that	  of	  Cyp1B1*3	  (16	  hours)	  (Table	  3.3).	  
A	  previous	   study	  by	   Ingelman-­‐Sundberg	  et	  al.	   (21),	   found	  a	   slower	  but	  non-­‐significant	  
difference	   in	   the	   rate	   of	   degradation	   between	   Cyp1B1*1	   (ancestral)	   and	   Cyp1B1*2,	  
which	  would	  be	  consistent	  with	  our	  results.	  The	  difference	  in	  our	  results	  could	  be	  due	  to	  
the	  fact	  that	  Ingelman-­‐Sundberg	  et	  al.	  (21)	  also	  compared	  Cyp1B1*2	  to	  Cyp1B1*1	  while	  
we	   compared	   Cyp1B1*2	   to	   Cyp1B1*3.	   The	   slower	   rate	   of	   degradation	   of	   Cyp1B1*2	  
could	  be	  due	  to	  an	  arginine	  to	  glycine	  substitution	  at	  position	  48	  in	  that	  could	  enhance	  











Table	   3.3	   Cyp1B1	   variants	   and	   half-­‐life	  
Degradation	  rates	  of	  variant	  Cyp1B1	  proteins	  were	  
measured	   and	   used	   to	   calculate	   the	   protein	   half-­‐
life.	  Cyp1B1*3	  was	  used	  as	  the	  ancestral	  version	  of	  
the	  protein	  with	  half-­‐life	  of	  16	  h.	  Each	  value	  is	  the	  
average	  of	   three	   replicate	  experiments.	   #	   signifies	  












Cell	  Type	   Cyp1B1	   Half-­‐life	  (h)	   P-­‐Value	  
BT20	   Cyp1B1*3	   16.3	   	  	  
	   	   	   	  T47D	   Cyp1B1*2	   24.3	   0.03#	  




folding	  and	  stability	  of	  Cytochrome	  P450	   family	  1	  and	  2	  proteins	   (21,	  59).	  Thus	  amino	  
acid	  substitutions	  that	  stabilize	  the	  folding	  of	  this	  region	  could	   increase	  the	  half-­‐life	  of	  
the	   protein.	   Bandiera	   et	   al.	   (44)	   showed	   that	   Cyp1B1	   was	   degraded	   through	   the	  
proteasome.	  To	  verify	  this	  result,	  we	  repeated	  the	  cycloheximide	  chase	  experiment	  as	  
described	   above,	   but	   we	   blocked	   proteasomal	   degradation	   with	   the	   proteasome	  
inhibitor	  MG132.	  For	  each	  of	  the	  three	  Cyp1B1	  variant,	  we	  found	  a	  two-­‐fold	  increase	  in	  
the	  half-­‐life	  of	   the	  Cyp1B1	  protein	   in	   the	  presence	  of	  MG132	   (Figure	  3.3).	   These	  data	  
demonstrate	   that	   the	   proteasome	   plays	   a	   key	   role	   in	   the	   degradation	   of	   Cyp1B1	   in	  
human	  cells	  confirming	  the	  observations	  of	  Bandera	  et	  al.	  (44)	  with	  Cyp1B1	  degradation	  
in	  monkey	  cells.	  	  
In	   conclusion,	   we	   were	   able	   to	   assess	   the	   effects	   of	   endogenous	   amino	   acid	  
substitutions	   on	   Cyp1B1	   protein	   half-­‐life	   by	   measuring	   the	   stability	   of	   the	   variant	  
proteins	   in	   human	   cell	   lines.	   For	   example	   we	   observed	   a	   half-­‐life	   of	   13.1	   h	   for	   the	  
Cyp1B1*4	  variant	  protein	  indicating	  that	  it	  degrades	  about	  25%	  faster	  than	  the	  rate	  of	  
the	  Cyp1B1*3	  protein	  (Table	  3.3).	  In	  contrast	  Bandiera	  et	  al.	  (44)	  found	  that	  Cyp1B1*4	  
had	   a	   5	   hour	   half-­‐life.	  We	   suspect	   that	   the	   5	   hour	   half-­‐life	   reflects	   the	   fact	   that	   the	  
degradation	  rate	  was	  measured	  in	  an	  African	  green	  monkey	  cell	  line	  where	  the	  human	  
Cyp1B1*4	  was	  over-­‐expressed.	  It	  is	  our	  hypothesis	  that	  the	  examination	  of	  endogenous	  
proteins	   in	  human	  cell	   lines	  would	  be	  closer	  to	  the	  actual	  degradation	  rates	   in	  human	  
tissues.	  Since	  we	  observed	  a	  much	  smaller	  yet	  significant	  difference	  in	  half-­‐life	  between	  





Figure	   3.3	   Cyp1B1*2	   degradation	   in	   the	   presence	   of	  
cycloheximide	  alone	  and	  cycloheximide	  plus	  MG132.	  Cells	  were	  
exposed	   to	  MG132	   over	   for	   8	   hours.	   At	   0,	   4,	   and	   8	   hours,	   cells	  
were	  harvested	  and	  Cyp1B1	  levels	  were	  measured	  using	  western	  
blotting	  techniques.	  The	  half-­‐life	  of	  Cyp1B1*2	  increased	  by	  188%	  
when	   MG132	   was	   used	   to	   block	   proteasomal	   degradation.	  
Cyp1B1*3	   and	   Cyp1B1*4	   increased	   by	   220%	   when	   MG132	   was	  
added.	   All	   time	   points	   are	   the	   average	   of	   three	   replicate	  
experiments.	  




xenobiotic	  metabolism	  in	  breast	  tissue	  would	  be	  very	  minor,	  and	  would	  have	  little	  to	  no	  



























CHAPTER	  4:	  SUMMARY	  




4.1	  Polymorphisms	  in	  Xenobiotic	  Metabolizing	  Genes	  
	   As	  a	  major	  pathway	  of	  detoxification	  for	  the	  human	  cell,	  xenobiotic	  metabolizing	  
enzymes	   (XME)	  work	   to	   reduce	  the	  effects	  of	  certain	   toxic	  and	  mutagenic	  compounds	  
that	  diffuse	  into	  the	  cell.	  Our	  study	  set	  out	  to	  examine	  any	  link	  between	  polymorphisms	  
in	   the	   phase	   I	   and	   phase	   II	   xenobiotic	   metabolizing	   pathways	   and	   breast	   cancer	   in	  
African	  American	  and	  European	  American	  populations.	  For	  phase	  I	  XME,	  we	  measured	  
the	  association	  between	  four	  common	  single	  nucleotide	  polymorphisms	  in	  Cytochrome	  
P450	   Family	   1	   Subfamily	   B	   Protein	   1	   (cyp1B1)	   gene	   and	   13	   patient	   and	   tumor	  
characteristics.	   Using	   logistic	   regression	   analysis,	   we	   found	   no	   significant	   association	  
between	  polymorphisms	  in	  the	  cyp1B1	  gene	  and	  breast	  cancer	  risk	  factors.	  It	  is	  plausible	  
that	  increased	  production	  of	  phase	  I	  products	  might	  increase	  the	  expression	  of	  phase	  II	  
enzymes.	  This	  would	  help	  to	  reduce	  the	  amount	  of	  mutagenic	  compounds	  produced	  by	  
Cyp1B1.	  Alternatively,	  since	  the	  production	  of	  mutagenic	  materials	  produced	  by	  Cyp1B1	  
protein	  is	  dependent	  upon	  substrate	  concentration,	  it	  is	  possible	  that	  a	  certain	  substrate	  
concentration	  threshold	  would	  have	  to	  be	  reached	  before	  any	  effect	  could	  be	  seen.	  	  
	   In	   addition	   to	   our	   work	   with	   cyp1B1,	   we	   also	   assessed	   possible	   associations	  
between	  polymorphisms	  in	  phase	  II	  XMEs.	  A	  major	  gene	  family	  in	  the	  detoxification	  of	  
xenobiotics,	   Glutathione	   S-­‐Transferase	   (GST)	   works	   by	   adding	   glutathione	   to	   reactive	  
metabolites,	   which	   converts	   them	   to	   large	   polar	   non-­‐reactive	   molecules.	   Many	  
European	   Americans	   and	   African	   Americans	   have	   gene	   deletions	   in	   GST	   Family	   Theta	  
Protein	  1	  (gstt1)	  and/or	  the	  GST	  Family	  Mu	  Protein	  1	  (gstm1)	  genes.	   It	   is	  thought	  that	  




19,	   36-­‐40);	   however	  we	   found	   no	   significant	   association	   between	   the	   absence	   of	   the	  
gstt1	  or	  gstm1	  genes	  and	  breast	  cancer	  risk	  factors.	  We	  hypothesize	  that	  the	  overlap	  of	  
substrate	   specificity	   with	   other	   GST	   enzymes	   may	   compensate	   for	   the	   loss	   of	   these	  
genes.	  	  
	   In	   summary,	   the	   analysis	   of	   cyp1B1,	   gstt1,	   and	   gstm1	   polymorphisms	   in	   473	  
European	  American	  and	  177	  African	  American	  breast	  cancer	  patients	  failed	  to	  show	  any	  
significant	  association	  between	  polymorphic	  variance	  and	  breast	  cancer.	  However,	   it	   is	  
possible	   that	   these	  polymorphic	   genes	   play	   a	  minor	   role	   in	   breast	   cancer	   progression	  
that	   our	   moderate	   sample	   size	   renders	   undetectable.	   	   Furthermore,	   studies	   into	   the	  
expression	  patterns	  of	  other	  phase	  II	  XMEs	  could	  be	  performed	  to	  assess	  how	  the	  cell	  
compensates	   for	   varying	   protein	   levels	   and	   catalytic	   activity	   of	   Cyp1B1,	   GSTT1,	   and	  
GSTM1.	  	  
4.2	  Cyp1B1	  Polymorphisms	  and	  Protein	  Stability	  
	   	  As	   the	   largest	   XME	   families	   in	   humans,	   Cytochrome	   P450	   enzymes	   work	   to	  
detoxify	   the	   cell	   from	   various	   toxins,	   carcinogens,	   and	   therapeutic	   drugs.	   In	   breast	  
tissue,	   Cyp1B1	   is	   the	   most	   highly	   expressed	   of	   any	   Cytochrome	   P450	   enzymes	   (13).	  
Cyp1B1	   often	   converts	   xenobiotic	   compounds	   to	   highly	   reactive	   carcinogens,	   and	  
previous	   studies	   have	   shown	   that	   common	   Cyp1B1	   single	   nucleotide	   polymorphisms	  
that	  lead	  to	  amino	  acid	  substitutions	  can	  affect	  the	  rate	  of	  carcinogen	  production	  (3,	  6,	  
18-­‐27,	  32,	  44).	  To	  determine	  whether	  these	  polymorphisms	  affect	  Cyp1B1	  stability,	  we	  




Through	  the	  use	  of	  cycloheximide	  chase	  and	  western	  blotting	  techniques,	  we	  were	  able	  
to	   measure	   the	   half-­‐life	   of	   Cyp1B1*2	   (Arginine	   to	   Glycine	   substitution	   at	   amino	   acid	  
position	   48	   and	  Alanine	   to	   Serine	   substitution	   at	   amino	   acid	   position	   119),	   Cyp1B1*3	  
(Leucine	  to	  Valine	  substitution	  at	  amino	  acid	  position	  432),	  and	  Cyp1B1*4	  (Asparagine	  
to	  Serine	  substitution	  at	  amino	  acid	  position	  453).	  We	  detected	  a	  20%	   increase	   in	   the	  
rate	  degradation	  for	  Cyp1B1*4	  compared	  to	  Cyp1B1*3,	  and	  a	  50%	  decrease	  in	  the	  rate	  
of	  degradation	  for	  Cyp1B1*2	  compared	  to	  Cyp1B1*3.	  Both	  of	  these	  findings	  are	  much	  
more	   modest	   compared	   to	   the	   three-­‐fold	   differences	   reported	   in	   the	   previously	  
published	   data	   (44).	   We	   suspect	   that	   the	   overexpression	   of	   the	   Cyp1B1	   proteins	   in	  
monkey	  cells	  might	  be	  responsible	   for	   the	  much	  greater	  differences	   in	  Cyp1B1	  variant	  
protein	  stabilities.	  	  
	   	  Previously,	   Bandiera	   et	   al.	   showed	   that	   Cyp1B1	   was	   degraded	   through	   the	  
proteasomal	   pathway	   in	   African	   Green	  Monkey	   cells	   (44).	   	   To	   verify	   this	   pathway	   in	  
human	  cell	   lines,	  we	  used	   the	  proteasomal	   inhibitor	  MG132	  along	  with	  cylcoheximide	  
chase	  and	  western	  blotting	   to	  measure	  Cyp1B1	  degradation	  over	  8	  hours.	   In	  all	   three	  
variants,	   we	   measured	   a	   two-­‐fold	   increase	   in	   half-­‐life	   when	   the	   proteasome	   was	  
inhibited.	  This	  result	  verifies	  that	  the	  proteasome	  plays	  a	  key	  role	  in	  the	  degradation	  of	  
Cyp1B1.	  	  
To	  further	  expand	  on	  this	  study,	  we	  plan	  to	  measure	  the	  half-­‐life	  of	  Cyp1B1*1,	  
Cyp1B1*5,	  and	  Cyp1B1*6.	  	  In	  addition,	  we	  plan	  to	  determine	  if	  amino	  acid	  positions	  119	  




present,	  studies	  measuring	  enzymatic	  efficiency	  and	  substrate	  specificity	  can	  be	  used	  to	  
examine	   the	   regulation	   of	   Cyp1B1*2	   and	   Cyp1B1*4.	   The	   resulting	   data	   illustrate	  
potential	  molecular	  mechanisms	   for	   previously	   published	   differences	   in	   breast	   cancer	  
risk	  (19,20,27).	  
4.3	  Cyp1B1	  stability	  and	  Breast	  Cancer	  Risk	  
	   As	  one	  of	  the	  most	  common	  forms	  of	  cancer	  in	  women	  in	  the	  United	  States,	  it	  is	  
imperative	   to	   determine	   the	   underlying	   mechanisms	   for	   breast	   cancer	   susceptibility.	  
Numerous	  studies	  have	  examined	  genetic	  polymorphisms	  within	  the	  human	  genome	  to	  
determine	  what	  effect	   they	  might	  have	  on	  breast	  cancer	  development	  or	  progression.	  
Through	  our	  population	  study	  with	  cyp1B1,	  gstt1,	  and	  gstm1	  genes,	  we	  were	  unable	  to	  
measure	   any	   significant	   correlation	   between	   breast	   cancer	   tumor	   characteristics	  with	  
genetic	  variance.	  These	  results	  are	  consistent	  with	  the	  modest	  differences	  in	  half-­‐life	  we	  
observed	   between	   the	   Cyp1B1	   variants.	   These	  modest	   differences	   in	   Cyp1B1	   protein	  
stability	   are	   likely	   to	   have	   a	   minimal	   impact	   on	   the	   production	   of	   carcinogenic	  
compounds	  and	  thus	  an	  even	  more	  minor	  effect	  on	  breast	  cancer	  risk.	  This	  is	  verified	  by	  
the	   numerous	   case	   control	   studies	   examining	   the	   impact	   cyp1b1	   mutations	   have	   on	  
breast	   cancer	   (19,20,27-­‐31)	   This	   conclusion	   argues	   against	   the	   previously	   published	  
hypothesis	  which	  proposes	  a	  link	  between	  cancer	  risk	  and	  Cyp1B1	  half-­‐life	  (44).	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